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Cycloaddition chemistry has historically served as a robust route to stereo-rich and highly 
functionalized cyclic and heterocyclic compounds. Herein we describe our examination of 3-
hydroxy-4-pyrone-derived oxidopyrylium cycloadditions in both mechanistic considerations as 
well as the unique synthetic advancements of their corresponding cycloadducts.  Chapter 1 is a 
literature review where we specifically outline the use of oxidopyrylium cycloadditions in the 
synthesis of natural products. This includes the mention of previous syntheses prior to 2008, and 
a more thorough examination of the natural products synthesized from 2008 to present. The work 
exploits this chemistry as a facile route to highly complex 7-membered natural products, among 
other unique structures.  
In Chapter 2, we look closer into the dimerization of the reactive intermediate in these 
cycloadditions, the oxidopyrylium ylide, and factors to which it is influenced by. Previously our 
lab found that 3-hydroxy-4-pyrone-derived dimers can be used as ylide surrogates in 
cycloaddition reactions. We found through kinetic and computational work that this was 
occurring via full reversibility of the dimer to the reactive ylide. In addition, the studies show 
that the methyl placement on isomers, maltol and allo maltol-derived ylides, substantially 
influences reactivity’s observed in both their dimerization and cycloaddition pathways. Due to 
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steric factors, maltol-derived ylides were shown to have a higher energy barriers to dimerization, 
making it possible to trap out the ylide rapidly with electrophilic dipolarophiles. Allo maltol-
derived ylides have lower energy barriers to dimerization, making trapping capabilities less 
efficient. We then showed that maltol-derived cycloadducts, to whose synthetic utility is not well 
known, undergoes rapid regiodivergent acid-mediated ring contraction cascades to guaiacol 
derivatives. These studies expanded upon the current known utility of 3-hydroxy-4-pyrone 
derived oxidopyrylium cycloadditions. 
 In Chapter 3 we continued to expand upon the synthetic utility of 3-hydroxy-4-
pyrone derived cycloadducts by developing a route to 2-methoxytropones via a samarium iodide- 
mediated reductive ring opening approach. Previously, our lab had primarily explored acid-
mediated approaches to biologically active highly oxygenated tropolones. However, the 
reductive ring opening provided a facile route to a novel A-C colchicine analog. Additionally, 
the A-C analog synthesized was shown to be highly atropisomerically stable, with computed 
energy barriers to rotation of greater than 35 kcal/mol, that was also supported experimentally. 
Biological assay data showed one atropisomer to be biologically active with a GI50 value of 0.4 
µm, and was approximately 10-fold more potent than its enantiomer. This methodology is 
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Oxidopyrylium Cycloaddition Chemistry as an Efficient Tool in Natural Product 
Synthesis   
1.1. Introduction  
Cycloaddition chemistry is among the most prevalent routes to complex natural products since 
the birth of synthetic organic chemistry. One of the most notable cycloadditions in natural product 
synthesis is the Diels-Alder reaction, which allows for the formation of multiple stereo and 
regioselective carbon-carbon bonds in one step. Oxidopyrylium cycloaddition chemistry, which 
occurs through formation of a reactive oxidopyrylium ylide (Scheme 1.1, 1.1), forms stereorich 
complex cycloadducts (1.2) with further bond forming potential and thus has also been used in 
many total syntheses efforts dating back to Sammes endeavors in 1983.1 Given this value, reviews 
covering various aspects of oxidopyrylium cycloaddition chemistry can be found throughout 
recent synthetic organic chemistry literature, with the most recent one being published in 2008.2 
However, since 2008 many significant advancements in oxidopyrylium chemistry have been made 
and thus we wrote a review describing these as well as the more recent natural product syntheses 
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synthesis sections of the review as well as new advancements in natural product synthesis since 
publication of the review through 2019.	 
A benefit to using oxidopyrylium cycloaddition chemistry is that the routes used to access the 
reactive oxidopyrylium ylide are manifold (Scheme 1.1). Early methods included oxidation of 
2,4,6-triphenyloxidopyrylium (not shown),4 and epoxyindenone rearrangements (1.5 → 1.6).5 
More common and recently utilized methods include forming the ylide through acetoxypyrone 
elimination (1.3 → 1.1)6 from an Achmatowicz generated pyran,7 and also through 3-hydroxy-4-
pyrone alkylation (1.7 → 1.8),8 or group transfer activation.9 Some other unique routes include 
forming the oxidopyrylium ylide via diazotransfer chemistry (1.4 → 1.1), which has also been 
utilized towards natural product synthesis.10 The ability to generate the ylides with a variety of 
different substrates and subject them to both inter- and intramolecular cycloadditions with a wide 
range of dipolarophiles speaks to the current utility and further potential of this reaction as a tool 
for synthetic organic chemists, and was extensively reviewed prior.2g 
8-Oxabicyclo [3.2.1] octanes are found in numerous biological constructs and thus 
oxidopyrylium cycloaddition chemistry has been used to synthesize natural products containing 
this scaffold. These constructs have also served as intermediates in the synthesis of other complex 
natural products emphasized in Figure 1.1, and which total syntheses were reviewed previously. 
2g, 11, 12 The novelty of these structures further highlights the usefulness and advantages to 






1.2. Synthesis of 8-Oxabicyclo [3.2.1] Containing Natural Products 
Since 2008, a few other 8-oxabicyclo [3.2.1] octane containing natural products were 
synthesized one of which being anthecularin (Scheme 1.2A), and another being englerin A 
(Scheme 1.2B). Anthecularin was isolated in 2007 by Karioti and Tasdemir and is known to have 
antiprotozoal activity.13 The natural product was successfully synthesized by Pattenden in 2009.14 
The synthesis was highly efficient, requiring only 7 steps. The intramolecular oxidopyrylium 
cycloaddition formed through acetoxypyrone elimination set all four of the molecules 
stereocenters and two of its’ four rings (1.11 → 1.13). Following the cycloaddition, only a 3-step 























X = O, Y = H, valeranone
X = H2, Y = H, valerane
X= O, Y = OAc, fauronyl acetate
(Sammes, 1983)
cryptofauronol





























































X = H, polygalolide A
X = OMe, polygalolide B
(snider, 2007)
Figure 1.1. Examples of natural products and close homologs with total syntheses enabled by oxidopyrylium cycloaddition
chemistry (1983-2007).
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Englerin A, first isolated in 2009 by Beutler and coworkers,15 is a stereorich oxabicylic 
natural product with notable anti-cancer activity specifically for kidney cells,16 making it a popular 
target for synthetic chemists. A few years after the elucidation of its structure and activity, several 
total syntheses were reported,17 one of them coming from the Nicolaou and Chen groups in 2010.18 
Their synthesis employed an intermolecular oxidopyrylium cycloaddition of pyrone 1.16 with 
chiral sulfonamide acrylate, 1.17, to generate 1.18 which was then able to be extensively modified 
to create the natural product. 	
 
1.3. Oxidopyrylium Cycloadditions in Total Syntheses of Troponoids  
 The 8-oxabicyclo [3.2.1] octanes serve as extremely useful intermediates in the synthesis 
of troponoids, a common class of 7-membered aromatic natural products. Baldwin emphasized 
this in 2002 by exploiting an oxidopyrylium cycloaddition/ring-opening method in the synthesis 



























































































































natural product synthesis efforts utilizing oxidopyrylium cycloaddition chemistry have been 
reported.  
Tchabanenko and coworkers accomplished an oxidopyrylium cycloaddition approach to 
the benzyl analog of troponoid natural product rubrolone (Scheme 1.3A, 1.25).19 Rubrolone and 
its chromophore rubrolone aglycon (Scheme 1.3A) are natural products popular for their reddish-
purple color and low cytotoxicity.20 Tchabenenko’s synthesis began with extremely cheap and 
readily accessible, 1.2 and 1.21. The oxidopyrylium cycloaddition built the entire carbocycle in 
one step, however, was found to have poor regioselectivity leading to the desired compound in 
only 35% yield (Scheme 1.3B, 1.2 → 1.22). Installation of a methoxy group (1.22 → 1.23) 
followed by an anionic ring-opening/oxidation sequence furnished the troponoid 1.24 in 3 steps, 
which was subsequently demethylated using boron tribromide to generate the benzyl analog of 
rubrolone aglycon, 1.25. A similar sequence was also carried out with the minor regioisomer, 
which also ultimately led to 1.25.  
Both hainanolidiol and harringtonolide were isolated in 1978 by Buta and coworkers,21 and 
had been the target of one prior total synthesis.22 In the Tang studies, the researchers employed the 
oxidopyrylium cycloaddition as a key step that created both the stereochemically dense caged 


















































Scheme 1.3A: Natural product rubrolone and chromophore, rubrolone aglycon. B: Synthesis of benzyl analog of 
rubrolone aglycon (Tchabanenko, 2010).
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of 1.29 formed from the cycloaddition was accomplished via an anionic ring opening and 
subsequently modified to the tropone core over several steps. Hainanolidol natural product was 
then able to be converted to harringtonolide in one step using lead acetate.   
One of the more well-known troponoid natural products is colchicine, whose medicinal 
potential has been known for centuries, and is used today for the treatment of gout among other 
inflammatory-type ailments.24 Colchicine has been the target for several notable syntheses,25 and 
oxidopyrylium cycloaddition has been considered as an option for its synthesis.26 Recently, this 
route has been developed by Li and coworkers (Scheme 1.5).27 Commercially available trimethoxy 
benzaldehyde was able to be modified to the furan intermediate 1.32. In one step 1.32 was 
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(3 steps from colchicine)
(+)-(4aS, 7S)-demecolcinone





(-)-colchicine, 9.2% overall yield, 
>99% ee
Scheme 1.5: Synthesis of troponoid natural products, (-)-colchicine, (+)-(4aS, 7S)-demecolcinone, and (-)-(aS, 7S)- metacolchicine (Li, 2017).
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base to undergo acetoxypyrone elimination and subsequent intramolecular oxidpyrylium 
cycloaddition necessary to obtain 1.34. From the cycloadduct a 4-step rearrangement was 
conducted to form colchicine in 9 steps, 9.2% overall yield and >99% ee. The chemistry was also 
used to access both demecolcinone and metacolchicine.  
Our group has been able to use 
oxidopyrylium cycloaddition chemistry 
for the synthesis of hydroxytropolones. 
This class of tropones have been found to 
bind to dinuclear metalloenzymes, leading 
to potency in a variety of biological 
assays.28 We have recently expanded upon 
this synthetic work to include 3,7- 
dihydroxytropolones,29 a scaffold present 
in the natural products puberulic and 
puberulonic acid (Scheme 1.6A).30 
Inspired by recent studies by Cox and 
coworkers on the biosynthesis of the 
related natural products stipitatonic and 
stipitatic acid,31 we synthesized the 3,7- dihydroxytropolone analog of stipitalide through a related 
approach (Scheme 1.6B). Notably, the use of oxidopyrylium dimer as the source of oxidopyrylium 
ylide was necessary in this process to limit a byproduct formed through alkyl chloride reduction 
































stipitalide, X = H
1.35, X = OH
stipitatonic acid, X = H
puberulonic acid, X = OH
[O] +H2O
-CO2
stipitatic acid, X = H
puberulic acid, X = OH
IMeO2C












































Scheme 1.6A: Closely related troponoid natural products and their 
biosynthetic relationship. B:Total synthesis of 2-hydroxystipitalide (Murelli, 2018).
1.35
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1.4. Biomimetically-Inspired Total Synthesis of Flavonoid-Derived Natural Products 
 3-Hydroxy-4-pyrones are found embedded in various flavonoids, and in the last several 
years there has been numerous total syntheses leveraging flavonoids as oxidopyrylium ylide-
generating synthons via photochemistry. Porco and co-workers have been at the forefront of this 
work in the synthesis of various rocaglates.32 One natural product among this class that was of 
particular interest was silvestrol, which has demonstrated exceptional anticancer activity.33 This in 
turn led to syntheses by both the Rizzacasa (Scheme 1.7),34 and Porco labs (Scheme 1.8).35 In 
Porco’s previous work with rocaglates he developed an excited state intramolecular proton transfer 
























































































Scheme 1.7: Rizzacasa group synthesis of silvestrol (Rizzacasa, 2007).
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This strategy was also utilized by both Porco and Rizzacasa in their total synthesis of silvesterol. 
The Rizzacasa approach used a racemic oxidopyrylium cycloaddition to generate (±)-1.47, which 
could be resolved upon coupling to optically pure, sugar-derived 1.52. The Porco lab, on the other 
hand, used TADDOL to promote the cycloaddition in 87% ee (1.55 → (+)-1.56). Besides this 
difference, the routes also differed in the synthesis of both the hydroxyflavone (1.42/1.43 vs. 1.53 
/1.55) and the dioxane (1.51 /1.52 vs. 1.57 /1.58) fragments.  
 
The natural products ponapensin and elliptifoline are produced from the same organisms 
as silvestrol, and share similar biosynthetic lineage. As such, in 2012 the Porco lab demonstrated 











































OMeX = , (+)-ponapensin
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Scheme 1.8: Porco group synthesis of silvestrol (Porco, 2007).
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compounds following stereoselective borane reduction (1.60 → 1.63) and subsequent amidation 
reactions (Scheme 1.9).36 
Another biomimetically-inspired advancement to oxidopyrylium cycloaddition chemistry 
stemmed from santalin Y, a yellow pigment component to red sandalwood.  Nohara and coworkers 
were the first to describe the isolation and structural elucidation of this compound and believed 
that it was formed through an isoflavylium-alkene cascade that could be viewed as a formal 
vinylogous oxidopyrylium cycladdition.37 This was the driving force behind the Trauner lab's total 
synthesis of santalin Y,38 whereby adding triethylamine to a mixture of compound 1.64 and alkene 
1.65 in trifluoroethanol furnished the target in exceptionally high yields (Scheme 1.10).	 
 
1.5. Other Total Synthesis Efforts 
Frondosin A is one class of frondosin molecules isolated from the marine sponge Dysidea 
frondosa.39 The molecules are able to disrupt interleukin-8 receptor binding, and are thus of 
therapeutic interest for inflammation.40 The class of molecules has also been of high interest to the 






















































Scheme 1.10: Total synthesis of santalin Y (Trauner, 2015).
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 Recently, Lee and coworkers used oxidopyrylium cycloaddition to complete the 7-
membered ring of frondosin A (Scheme 1.11),42 intercepting an intermediate used by Trost (1.73) 
in his own synthesis.43 In this case the alkene tethered furan forms the acetoxypyrone followed by 
immediate ylide formation and cycloaddition all in one step. The intramolecular oxidopyrylium 
cycloaddition step set the correct stereochemistry for the natural product’s aryl appendage (1.72).  
 
 Brownin F was isolated in 1994 by Ohmoto from the wood of Harrisonia brownin, and no 
total synthesis currently exists.44 However, Chouraqui and Commeiras recently demonstrated that 
spirocycles reminiscent of those found in the natural product could be rapidly accessed by 























































































Scheme 1.12: Synthesis of spirocyclic core of brownin F (Chouraqui, Commeiras, 2013).
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 Arteminolides are a class of natural products isolated by Kwon and coworkers from 
Artemsia sylvatica (Scheme 1.13A).46 The molecules have the potential to be anti-cancer 
compounds due to their strong inhibitory activity against farnesyltransferase, and no total synthesis 
has been reported to date. Sohn has been exploring silicon, both in terms of vinyl silanes and as 
part of tethers, in the synthesis of highly functionalized 7- membered rings which has offered a 
potential strategy to these compounds (Scheme 1.13).47 Sohn has synthesized 3 different highly 
functionalized scaffolds, (1.78, 1.83, and 1.88) that are proposed to be potential precursors towards 
the targets (Scheme 1.13B-D).  
 
Recently, the Li group employed their type II intramolecular cycloaddition chemistry 
towards the synthesis of eurifoloid A (Scheme 1.14).48 Eurifoloid A is one of a group of ingenol 
derivatives that are of interest to synthetic organic chemist’s due to the stereochemically dense 
nature of the targets, as well as their remarkable biological activity ranging from anti-tumor to 























































































Scheme 1.13A: Arteminolide natural products. B-D: Efforts towards their total synthesis (Sohn, 2009, 2010, 2014).
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furan 1.90 in only 3 steps from commercially available 1.89. Achmatowicz-rearrangment and 
subsequent cycloaddition led to the carbocylic core of the ingenols. Bis-reduction produced one of 
the desired alcohols with the	according stereochemistry necessary for the targets. Unfortunately, 
attempts at an oxidation/Meinwald rearrangement led to the incorrect bridgehead stereochemistry 
for the natural product (1.93). 
 
1.6. Intricarene Revisted 
Intricarene is a natural product that has remained of high interest to multiple groups. In 
2006 both Trauner and Pattenden groups successfully synthesized the molecule.12k,12l Each group 
employed a transannular oxidopyrylium cycloaddition as the final step in the synthesis (Scheme 
1.15). Due to the fact that the oxidopyrylium ylides in both cases were synthesized from the natural 
product bipinnatin J, each group suggested this could represent the biomimetic pathway to the 
natural product. However, later on the Tantillo lab carried out calculations on the oxidopyrylium 
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Scheme 1.15: Overview of biomimetically-inspired syntheses of intricarene from bipinnatin J (Pattenden, 2006 and Trauner, 2006).
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20 kcal/mol.50 These relatively high calculated energy barriers along supported by the high 
temperatures the Pattenden and Trauner groups needed to facilitate the cycloaddition raised doubts 
as to whether these routes were biomimetic. In 2014, the Trauner and de Vivie-Riedle groups 
disclosed their serendipitous findings of a sequence that led to intricarene under more biologically 
consistent conditions (Scheme 1.16).51 In the course of synthetic work towards another related 
natural product, bielschowskysin, the group had synthesized 1.98 through methanolysis and singlet 
oxidation of bipinnatin J. When 1.98 was dissolved in 1:1 deuterated acetone and water and 
irradiated with a reptile lamp they in fact isolated intricarene in 25% yield.  
Computational modeling demonstrated the feasibility of a triplet diradical (1.100), which 
would then undergo stepwise, radical-based cycloaddition (1.100 → 1.101 → intricarene). The 
need for the methyl ether of 1.97 to promote the entire reaction sequence coupled with the noted 
use of methanol/dichloromethane during the natural product isolation, led the authors to raise the 
possibility that intricarene may not be a true natural product but rather an artifact of isolation.	 
 
 

















































1.7. Natural Product Synthesis Efforts Employing Oxidopyrylium Cycloaddition 
Chemistry in 2017-2019 
 Since 2018 the Li group has successfully advanced efforts in three natural product 
syntheses all employing oxidopyrylium cycloaddition chemistry as a key step. Among these 
includes a member of the bufadienolides, bufogargarizin C which was isolated from the venom of 
Bufo bufo gargarizans by Ye and co-workers in 2010 (Scheme 1.17).52 This class of molecules is 
well known for their ability to inhibit Na+/K+-ATPase and thus have attracted attention as potential 
targets for anticancer drugs following the recent discovery of the signaling pathways.53 Both 
bufogargarizin C and bufogargarizin A contain an unusual 7/5/6/5 ring system, contrary to other 
bufadienolides containing a 6/6/6/5 skeleton. Li and coworkers utilized a Bronsted acid-mediated 
intramolecular [5 + 2] cycloaddition to offer both a regio- and diastereoselective route to the 





































































































synthesize the acetoxypryone-derived starting material for the oxidopyrylium cycloaddition from 
the achmatowicz-derived furan they received both 1.104 and 1.105. After treating 1.104 with acetic 
anhydride, base, and DMAP, synthesis of the appropriate acetoxypyrone precursor was not 
successful. Additionally, from 1.105 they were unsuccessful at completing the desired [5 + 2] 
cycloaddition via elimination due to the anomeric hydroxyl causing steric hindrance. They instead 
opted to use the Bronsted acid trichloroacetic acid to allow for elimination and enolation. To date 
this is the first example of an acid-mediated intramolecular [5 + 2] cycloaddition of an allene 
moiety. This is significant as it also introduces a new way to access the reactive oxidopyrylium 
ylides rather than through group elimination and transfer strategies. The synthesis provides five 
out of eight of the stereo centers in the natural product and Li and coworkers are working to 
streamline this synthesis towards the natural products.  
In even more recent efforts the group accomplished the total synthesis of cerorubenic acid-
III,55 a unique sesterpenoid first isolated by Naya and coworkers in 1983 from the insect 
Ceroplastes rubens Maskell (Scheme 1.18).56 A lack of natural sources exists to access the natural 
product and thus the development of an efficient synthesis to examine further biological activity 
is desirable. However, its synthesis presents a formidable synthetic challenge as it contains seven 
contiguous stereocenters and is highly strained, containing an anti-Bredt double bond that readily 
oxidizes to the epoxide when exposed to air. The acetoxypyrone derived intramolecular [5 + 2] 
oxidopyrylium cycloaddition allowed for the diastereoselective construction of the bicycle [4.4.1] 
ring system with the anti-Bredt double bond in the final product (1.112). In the synthesis, they 
found that chemoselective reduction of the C4-O and C5-O bonds was challenging due to the 
presence of an allylic C24-O bond. However, converting C5-hydroxyl to the corresponding 
bromide and treating this with sodium napthalenide selectively eliminated the C4-O bond, 
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removed the benzyl group, and unusually reduced the less sterically hindered C4-C5 double bond. 
Subsequent transannular cyclization and cross metathesis lead to the desired natural product in 16 
steps. 
Vinigrol is a biologically active member of the diterpene family isolated from the fungal 
strain Virgaria nigra F-5408.57 The natural product is known to inhibit human platelet aggregation 
and is an antagonist of tumor necrosis factor (TNF-a).58 The strained bicycle [5.3.1] undecane ring 
system in vinigrol is an unusual bridged framework that is also present in the well-known terpene 
taxol,59 and its’ complex structure and pharmacological properties has made it of synthetic interest 
for more than three decades.60 All previous syntheses utilized Diels-Alder as the key step. 
However, in 2019 the Li group synthesized vinigrol using a type II intramolecular [5 + 2] 
cycloaddition (1.117 → 1.118), followed by a ring-contraction leading to the synthetically 
challenging 1,5-butanodecahydronapthalene core with 8 stereocenters (Scheme 1.19).61 Li’s use 
of an acetoxypryone-derived intramolecular [5 + 2] cycloaddition exploits a new route to the 

















































































Scheme 1.18: Synthesis of cerorubenic acid-III and cerorubenic acid-III methyl ester (Li, 2019).









in the literature pertaining to intramolecular [5 + 2] cycloaddition reactions of aliphatic ring-fused 
oxidopyrylium ylides to construct eight-membered ring systems in natural product synthesis.  
  
Another natural product synthesis publication by the Li group was published in 2017 but 
not mentioned in the review and was an improvement upon the previous colchicine synthesis and 
also included the synthesis of b-lumicolchicine and allocolchicinoid N, Acetylcolchinol-O-methyl 
Ether (NCME).62 In this work, they were able to reduce the number of steps from the oxabicyclic 

































































(-)-colchicine, 9.3% overall yield
>99% ee
































Subjecting 1.120 to the Wacker oxidation and double elimination conditions developed by Cha in 
his total synthesis,63 furnished colchicine in 8 steps, 9.3% overall yield and >99% ee. Irradiation 
of colchicine lead to the unique 4p electrocyclization of b-lumicolchicine, and further irradiation 
lead to subsequent decarbonylation and an electrocyclic ring opening to NCME.  Li’s extensive 
natural product work further emphasizes the value of oxidopyrylium cycloaddition reactions 
towards troponoid and other complex natural products and its continued use in the development 
of novel chemical methodology. 
1.8. Conclusions 
 The highly complex and unique natural products and their syntheses presented in this 
chapter exploit the invaluable potential of oxidopyrylium cycloaddition chemistry. Specifically, in 
the construction of synthetically challenging stereorich 7-membered oxygenated ring systems, to 
which few other methodologies offer such consistent success towards. In addition, the abundance 
of the furan starting materials and reliability of the Achmatowicz reaction further solidifies this. 
As well as the potential for other routes, such as from naturally occurring pyrones, to offer even 
more easily accessible ways in forming the reactive ylide and thus varied oxabicyclic structures.  
In summary, there are a wealth of methods to access ylides and the several elegant total syntheses 
and efforts that have emerged in the past decade highlight oxidopyrylium cycloadditions long-
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 Mechanistic and Synthetic Studies of 3-Hydroxy-4-Pyrone-Derived Oxidopyrylium Species  
 
2.1. Introduction 
 3-Hydroxy-4-pyrone-derived oxidopyrylium cycloadditions have offered a versatile route 
to unique oxabicyclic compounds1 and their synthetic utility is enhanced by the fact that there is 
an abundance of naturally occurring and commercially available hydroxy pyrones such as maltol, 
kojic acid, and 3-hydroxyflavone (Scheme 2.1A). The first group to examine the synthetic 
practicality of this class of oxidopyrylium cycloaddition chemistry was Garst’s (Scheme 2.1C).2 
Garst synthesized tethered kojic acid derivatives (2.8) and heated them to produce a group transfer 
activation of the carbonyl and the neighboring hydroxyl group to form the reactive ylide, 2.9, 
which subsequently undergoes an intramolecular cycloaddition (2.9 → 2.10) with the tethered 
dipolarophiles to form functionally rich cycloadducts (2.11-2.14). Wender and Mascareñas were 
the first to exploit an intermolecular methodology for this chemistry through the synthesis of a 
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Scheme 2.1A: Representative examples of naturally occuring 3-hydroxy-4-pyrones. B: Kojic acid-derived intermolecular oxidopyrylium




could undergo intermolecular cycloadditions (2.2 → 2.3) in the presence of electron-deficient 
dipolarophiles to form cycloadducts 2.4-2.7.3 Later on, the Li group also expanded on the use of 
methyl triflate to acess 3-hydroxy-4-pyrone-derived oxidopyrylium ylides for both intramolecular 
and intermolecular dearomative indole cycloadditions.4 Aside from this work, not nearly as much 
research has been dedicated to the mechanistic and synthetic understanding of 3-hydroxy-4-
pyrone-derived oxidopyrylium cycloaddition chemistry compared to the acetoxypyrone-derived 
route to form oxidopyrylium ylides for cycloadditions.1o   
2.2. Murelli’s Previous Work on 3-Hydroxy-4-Pyrone-Derived Oxidopyrylium 
Cycloadditions and their use as Intermediates Towards the Synthesis of Tropolones 
 
The Murelli group advanced the understanding of kojic acid-derived intermolecular 
oxidopyrylium cycloadditions by completing a substrate scope and assessing reaction conditions 
to further improve the method.  The reaction works very well with electron deficient 
dipolarophiles, which is consistent with the nucleophilic nature of this type of oxidopyrylium ylide. 
Our lab further examined the utility of this reaction by subjecting the oxabicyclic products obtained 
from the-3-hydroxy-4-pyrone-derived oxidopyrylium cycloaddition chemistry (Scheme 2.2, 2.15 
→ 2.16) to an acid-mediated ring opening and demethylation route to access hydroxytropolones 
(2.17).5 Hydroxytropolones are highly oxygenated troponoids, which are a class of naturally 
occurring seven membered aromatic rings. Our group has used this chemistry to synthesize over 



































Scheme 2.2: Murelli’s synthetic route to tropolones and their representative biological mode of inhibition to 
metalloenzymes.
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di-nuclear metallo enzymes7 present in a variety of viruses such as herpes simplex virus8 and HIV 
(2.18).9 
Another early contribution of the Murelli group to oxidopyrylium cycloaddition literature 
was the report of being able to use the isolatable dimer (2.19) as a source of ylide to form 
cycloadducts when heated in the presence of 
dipolarophiles (Scheme 2.3).5 The formation 
of dimer from oxidopyrylium ylides has oft 
been reported as a problem with regards to 
achieving the formation of cycloadducts.10 
Therefore this was a significant discovery as it 
allows for these cycloadditions to be done in the absence of base, the presence of which can pose 
challenges when working with base-sensitive alkynes. In Wender and Mascareñas’s original work, 
they attempted to trap out the ylide prior to dimerization with dipolarophiles by using slow addition 
of a weaker base to keep overall concentration of ylide low (Scheme 2.3, 2.2 → 2.20). This method 
worked well for electron-deficient dipolarophiles such as dimethylacetylene dicarboxylate 
(DMAD) and N-phenylmaleimade affording good yields at low temperatures, but was less 
effective for weakly activated alkynes where only dimeric product is observed.3 Therefore, the 
novel discovery that the dimer can be used as an isolated source of ylide in the cycloaddition has 
resulted in great synthetic value for the facile synthesis of oxabicycles and ultimately tropolones 
by offering shorter reaction times and the ability to run reactions in the absence of base that could 
further complicate reaction conditions. 
The use of dimer in these cycloadditions has also allowed for improvements in the 
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Murelli’s oxidopyrylium dimer route to cycloadducts:




Scheme 2.3: Comparison of Wender’s initial work on kojic acid-derived
oxidopyrylium salts for cycloadditions (bottom) and Murelli’sdiscovery 
and use of an oxidopyrylium dimer for cycloadditions (top).
Me2NPh
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in which using the dimer led to substantially 
higher yields than when forming the ylide in 
situ, and produced a variety of functionally 
diverse oxabicyclic compounds (2.24-
2.27).11 Our lab has also showed that the use 
of the dimer allows for the reaction to be run 
with 1:1 equivalents of ylide to alkyne, and 
thus upon reaction completion and in the absence of base, no further workup or purification is 
required. The reaction could subsequently be used	in a highly efficient solid-phase synthesis of a-
hydroxytropolones. Not only has using isolated dimer offered	 benefits in terms of forming 
functionally dense oxabicyclic compounds, but also in forming sterically rich cycloadducts. Work 
done by the Brenner-Moyer group at 
Rutgers university in collaboration with 
our lab accomplished the first ever 
asymmetric method for 3-hydroxy-4-
pyrone-derived oxidopyrylium 
cycloadditions (Scheme 2.5, 2.19 → 
2.30).12 The Brenner-Moyer group utilized iminium activation of amines (2.28) with beta 
substituted enals (2.29).  When the reaction was done using the oxidopyrylium dimer, 
stereoselectivity of the reaction was improved with enantioselectivies approaching 99%.   
The use of oxidopyrylium cycloaddition chemistry as an intermediate to the synthesis and 
discovery of biologically active tropolones has largely dictated the research done in our group to 













































Scheme 2.5: The Brenner-Moyer groups use of 2.19 as starting material for
a highly enantioselective route to oxabicycles using chiral  imine catalysts
with cinnamaldehyde derivatives.
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Scheme 2.4: Discovery of a. 3-component oxidopyrylium cycloaddition using




their reported therapeutic potential. However, understanding oxidopyrylium cycloaddition 
chemistry and the nature of the [5 + 3] dimerization is arguably of broader interest to the scientific 
community as cycloaddition chemistry has long been proven to be able to form structurally 
complex molecules and offer vast fundamental chemical knowledge.1o  
2.3. Initial Studies on the Dimerization and Cycloaddition Pathways of 3-Hydroxy-4-Pyrone-
Derived Oxidopyrylium Ylides  
 
Although the synthetic value of using isolated oxidopyrylium dimer in the synthesis of 
oxabicyclic compounds and tropolones has been emphasized in section 2.2, a full understanding 
of the dimerization process for 3-hydroxy-4-pyrone derived oxidopyrylium ylides and its 
implications had not been previously studied and is potentially of high value due to the difficulty 
in controlling the otherwise reactive state of the neutral form. The inability to directly detect the 
reactive ylides serves as a confounding problem in understanding the nature of their dimerization, 
as well as using the dimers in synthesis. For example, it could be hypothesized that the dimerization 
is reversible which may or may not explain how the dimers can react with dipolarophiles to form 
cycloadducts. However, it is also possible that the dimers react directly with certain dipolarophiles 
to form cycloadducts. Our group wanted to examine different 3-hydroxy-4-pyrone-derived starting 
materials to understand more factors that influence oxidopyrylium ylides’ path to dimerization 
compared to cycloaddition, and offer experimental and theoretical evidence for the reversibility 
and general reactivity of these dimers. 
Our studies began by synthesizing an alternative oxidopyrylium triflate salt from 
commercially available and inexpensive maltol. Maltol is a natural product used as a flavor 
enhancer in foods and derived from the bark of larch tree, pine needles, and roasted malt. We 
subjected maltol to dimerization conditions we previously reported of the kojic acid (allomaltol)-
derived salt, 2.2. Interestingly, this dimerization took much longer (2 hours) with triethylamine as 
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compared to the allomaltol-derived oxidopyrylium salt (5 minutes) (Scheme 2.3) and produced 
two regioisomeric dimers (Scheme 2.6A, 2.31 → 2.33 + 2.34).  The	difference in dimerization 
time suggested either deprotonation of 2.31 was slower, possibly due to steric factors of 2.2 vs 
2.31, and/or the actual dimerization process itself is slower. We examined this question in depth 
by treating 2.2 or 2.31 with 0.8 equivalents of different bases ranging in their bulkiness (Hunig’s 
base, triethylamine, N,N-diisopropylaniline, and N,N-dimethylaniline) and monitoring the 
formation of dimeric products (2.19 and 2.33 + 2.34 respectively). In the case of 2.2, full 
conversion (80%) was seen for all bases after only 5 minutes except for N,N-dimethylaniline. For 
2.31, it took close to two hours to reach full conversion for triethlyamine and hunigs base, with 
N,N-diisopropylaniline never reaching full conversion. There was no product formation observed 
when N,N-dimethylaniline was used. The dimerization trends were based on the relative pKa’s of 
the bases and not based on 
sterics, implying that the 
slower deprotonation was 
not simply due to the methyl 
on 2.31 being closer to the 
site of deprotonation. We 
then subjected 2.33 + 2.34 to 
cycloaddition conditions 
with DMAD and found that 
the reaction was much more 
sluggish to form cycloadduct 

















































































































Scheme 2.6A: Synthesis of a maltol-derived oxidopyrylium salt and its formation of two regioisomeric
dimers. B: Effect of different bases on rate of dimer formation. C: Comparing products for reaction of 
2.2 and 2.31 with kinetically comparable bases determined in B for deprotonation in the presence
of DMAD.
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compared to cycloaddition of 2.19 and DMAD. It was curious that both the dimerization and 
cycloaddition differed so drastically between 2.21 and 2.32 just based on placement of the methyl 
group. The next step was to understand how the cycloaddition compared between 2.21 and 2.32 
when using a base that deprotonated each salt at a comparable rate (Scheme 2.6B, 2.2 with N,N-
dimethylaniline shown in red and N,N-diisopropylaniline with 2.31 shown in blue) in the presence 
of DMAD. In the case of 2.2 we hypothesized that the use of a weaker base could result in a lower 
concentration of ylide in solution and therefore better trapping capability with dipolarophile like 
Wender had shown (Scheme 2.3). This was in fact the case as we saw a 2:1 ratio of 2.19 to 2.20 
whereas previously only dimer was observed immediately. However, when 2.31 was subjected to 
the same reaction conditions with a comparable base, only bicyclic product was observed (2.35) 
and no conversion to dimers 2.33 and 2.34 was seen. This result was unexpected as it again 
emphasized the drastic differences seen between the reactivity of oxidopyrylium ylides 2.32 and 
2.21 in both their dimerization and cycloaddition pathways. The above experimental results made 
it evident that the differences in DMAD trapping efficiency from salt 2.2 and 2.31 prior to 
dimerization could not be fully explained by simple differences in rates of deprotonation, and thus 










2.4. DFT Calculations 
To gain a better understanding of the reactivity differences between 2.32 and 2.21, 
B3LYP/6-31G(d,p) calculations were employed thanks to Alec and Edyta Greer at Brooklyn and 
Baruch colleges respectively. Similar DFT calculations have been used to assess the tendency for 
compounds to dimerize,13 and in cycloadditions involving oxidopyrilium ylides.14 Since 2.32 and 
2.21 are structural isomers, their relative energies can be accurately compared. In this case the 
global minimum is the complex of 2.21. The results of the calculations showed that the formation 
of dimer 2.19 from the allomaltol-derived oxidopyrylium ylide 2.21 proceeds through a step-wise 
process (Scheme 2.7A). The mechanism involves an initial carbon-carbon bond formation via an 
aldol-like process between the a-carbon of the embedded enolate of one ylide, and the more 
sterically unencumbered electrophilic carbon of the other. The reaction ΔH‡ is 8.3 
kcal/mol (compared to ylide 2.21) and leads to the second step, where a more sterically 
encumbered carbon creates the second carbon-carbon bond of 2.19. In the formation of dimer 2.19, 
there is a methyl-methoxy gauche interaction, but it is lower in energy, likely due to the fact that 
it is an intermolecular process (TS-2, Figure 1). Conversely, the formation of dimer 2.33 from 
maltol-derived oxidopyrylium ylide 2.32 proceeds through an asynchronous concerted process 
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(Scheme 2.7B). The dimerization 
of 2.32 is higher in energy than the 
dimerization of 2.21 due to an 
unfavorable methyl-methyl gauche 
interaction, producing a ~2 kcal/mol 
higher transition state energy (i.e., 
ΔH‡ of 11.6 kcal/mol) than that 
of 2.21 (TS-3, Figure 2.1). An 
identical ΔH‡ of 11.6 kcal/mol energy 
barrier exists in the transition state to dimer 2.33.  Even though sterics of a methoxy group are 
generally lower in energy than a methyl group, this specific methoxy-methyl gauche 
interaction appears to have added steric strain, where the methyl group of the methoxy extends 
over the incipient carbonyl group (TS-4, Figure 2.1).  This explains why both dimers of 2.32 are 
formed, in contrast to the selective [5 + 3] dimerization of 2.21.   
  The cycloaddition reactions between DMAD and either 2.21 or 2.32 were fairly analogous 
energetically, and each was predicted to proceed through a concerted, asynchronous pathway. The 
transition state between DMAD and 2.32 was only slightly favored over that between DMAD and 
2.21 (11.7 vs. 12.9 kcal/mol).  Furthermore, cycloaddition products were thermodynamically 
favored over dimer products by approximately 40 kcal/mol in both cases. This is consistent with 
the observations that, with enough time and energy, all of the dimers studied can be converted to 




2.5. Kinetic Studies 
In order to evaluate the relative transition state energy barriers for dimerization and 
cycloaddition processes of the allomaltol-derived and maltol-derived oxidopyrylium ylides we 
calculated rate orders. Precedence for these studies was brought about by Brown et al in their 
kinetic studies on the reaction between dialkylborane dimers and alkenes.15 Similar to their studies, 
steady state approximation could be employed to evaluate the reaction of dimer (2.19/2.33/2.34) 
and DMAD in their formation of corresponding cycloadducts. The reaction was heated in 
deuterated toluene in the presence of an NMR standard and thus the changing concentrations of 
DMAD and the dimer could be monitored over time. In order to obtain the proper rate equation, 
two reactions were run:	one where the dimer is the limiting reagent (DMAD is in excess), and one 
in which DMAD is the limiting reagent (dimer is in excess). The results for the maltol-derived 








































Figure 2.2: Rate data describing the reaction of DMAD with dimer 2.33 when DMAD is the rate limiting reagent 
(left) and when 2.33 is the rate limiting reagent (right). 
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The graphs used to form the equation 1 show for the reaction of excess 2.33 and DMAD 
the decrease in concentration of DMAD followed 0th order kinetics. With respect to the dimer 
(2.33), the reaction was 1st order, as the ln[dimer] was a straight line. The reaction order implies 
the rate limiting step for the cycloaddition with DMAD is related to the reversibility of the dimer. 
As expected, the same reaction order was obtained for the regioisomeric dimer, 2.34 (graph not 
shown). 
The kinetic data obtained for the allomaltol-derived oxidopyrylium ylide differed from 









Graphs used to form equation (2) reveal that the reaction is 1st order in DMAD and ½ order in 
dimer. This is what would be expected for full reversibility back to the ylide, based on what Brown 
had found in his studies. This implies the rate limiting step is the cycloaddition reaction of 2.32 
with DMAD. Due to the different temperatures required for the reactions, comparing experimental 



































Figure 2.3:  Rate data describing the reaction of DMAD with dimer 2.19 when DMAD is the rate limiting reagent 
(left) and when 2.19 is the rate limiting reagent (right). 
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to the fact that the dimerization pathway for 2.32 is higher in energy than the dimerization pathway 
for 2.21, making the formation of dimer 2.19 the kinetic product. This also explains why no 
allomaltol-derived oxabicycles are observed when DMAD is present. Conversely, in the reaction 
of maltol-derived ylide and DMAD, the cycloadduct is the kinetic product explaining why 
intercepting of the maltol-derived oxidopyrylium ylide is observed with DMAD (Scheme 2.6C).  
2.6. Dipolarophile Dependence 
Although the dimerization energy pathways for the allomaltol-derived oxidopyrylium ylide 
and maltol-derived oxidopyrylium ylide are fixed, the studies suggest that in the presence of either 
more or less electron deficient dipolarophiles (where the cycloaddition energy pathway would be 
highered or lowered respectively) different trapping efficiencies between 2.21 and 2.32 could be 
observed. Data on this would further confirm and assess the practicality of choosing reaction 
conditions, for example, when it is optimal to use isolated dimer or to start from salt and base.  
	 For these studies, we added N,N-diisopropylaniline to a solution of CD3CN containing 
oxidopyrylium salts 2.2 and 2.31 and a panel of dipolarophiles of varying reactivity (2.37a-d), and 
monitored reaction progress by 1H NMR using the internal NMR standard, 3,5-di-tert-butyl 
toluene (Scheme 2.8).  Phenylacetylene (2.37d) is known to react more sluggishly with 2.2 than 
DMAD (2.37a). Transition state energy barriers were computed for the reaction of 2.37d with 2.2 
to form 2.36f (ΔH‡ = 16.3 kcal/mol) and for the reaction of 2.37d with 2.31 to form 2.37c (ΔH‡ = 
17.4 kcal/mol). As these energy barriers are each higher than their respective dimerization energy 
barriers, dimerization products should be the kinetic products in both instances. Consistent with 
this hypothesis, when N,N-diisopropylaniline was treated to a mixture of 2.37d and either salt 2.2 
or 2.31, upon complete consumption of salts, only dimerization products were observed. 
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For a more reactive dipolarophile, we turned to the highly electrophilic 4-phenyl-1,2,4-
triazole-3,5-dione (PTAD, 2.37b, see entry for products 2.36a/d). As anticipated, very low 
transition state energy barriers were calculated for the reaction between 2.37b and both 2.2 (ΔH‡ 
= 2.7 kcal/mol) and 2.31 (ΔH‡ = 3.1 kcal/mol).  As these barriers were each substantially lower 
than those of their respective dimerization reactions, 2.36a and 2.36d would both be expected to 
be the kinetic products.  Consistent with this, when N,N-diisopropylaniline was treated to a mixture 
of 2.37b and either salt 2.2 or 2.31, no dimer was observed and the [5 + 2] cycloaddition products 
2.36a and 2.36d predominated.  These two sets of experiments demonstrated that with the more 
extremes on the dipolarophile reactivity spectrum, trapping efficiency of the two salts are similar.  
However, when these experiments were performed with the more intermediately reactive 
dipolarophile methyl propiolate (2.37c, see entry for products 2.36b/e), differences in the trapping 
efficiencies of 2.2 and 2.31 returned. Specifically, when salt 2.2 was treated to the base in the 
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Scheme 2.8: Ratio of product to dimer when diisopropylaniline is added to salts 2.2 
and 2.31 in the presence of a wide range of dipolarophiles.
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were observed in the analogous reaction with 2.31.	These trapping studies helped to support both 
the experimental and kinectic data described in sections 2.4 and 2.5 regarding the overall unique 
reactivity differences between maltol and allomaltol-derived oxidopyrylium ylides.16 
 
2.7. Synthetic Studies on Maltol-Derived Oxidopyrylium Cycloadducts 
 Although our group has extensively examined the synthetic benefits of 3-hydroxy-4-
pyrone-derived oxidopyrylium cycloadditions from kojic acid-derived starting materials in the 
synthesis of 7-hydroxytropolones (section 2.2, Scheme 2.2), no further synthetic studies on its 
isomeric counterpart maltol had been examined by our lab or in the literature. After showing the 
methodology available to make a variety of maltol-derived oxabicycles as described in section 2.6, 
we wanted to subject them to the same ring-opening conditions we had developed for kojic-acid 
derived oxabicycles, specifically, the use of boron trichloride and sulfonic acid-mediated 
rearrangements.5,6 Our hypothesis was that the alternative positioning of the methyl group might 
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Scheme 2.9A: Hypothesized route to 4-hydroxytropolones. B: Synthesis of oxabicycles from 




























aryl containing bicycles (2.36c) that could stabilize the carbocation intermediate (2.38). Therefore, 
we first synthesized a variety of maltol-derived oxabicycles from cycloadditions with aryl 
acetylenes (Scheme 2.9B, 2.36c, 2.40a-f). However, when we tried the ring-opening conditions 
with phenylacetylene-derived cycloadduct 2.36c, use of boron trichloride resulted in the formation 
of the de-methylated ring contraction product 2-methoxy-5-arylphenol molecule (Scheme 2.10A, 
2.43a) and use of sulfonic acids resulted in regioisomeric opening of the ring followed by ring 
contraction to form 2-methoxy-4-aryl-6-methylphenol (Scheme 2.11, 2.49a). This result was 
novel, and emphasized some interesting differences between the isomeric maltol and allomaltol-
derived oxabicycles and regiodivergent pathways to the aromatic products depending on the nature 
of the acid. The 2-methoxyphenol (guaiacol) products constitute a class of naturally occurring 
benzene derivative and are embedded in countless natural products17 and biologically active, 
particularly anti-cancer, synthetic constructs (Figure 2.4).18 This oxidopyrylium route to their 
formation is not precedented and therefore we wanted to examine the reaction more in depth. 
 
In the case of allomaltol-derived oxabicycles, the carbocation formed is stabilized by being on a 
tertiary center and donation from the alpha-methoxyenone. However, for the maltol-derived 
oxabicycle, our current hypothesis (Scheme 2.10A) is that in the presence of boron trichloride the 
ring can open towards the carbonyl giving the secondary carbocation that can be stabilized through 




















Figure 2.4: Examples of anti-cancer natural products and synthetic constructs 
possessing guaiacol-aryl appendages.
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followed by a ring contraction and deacetylation (2.42) to give the stable aromatic biphenyl 
product (2.43a). A thorough substrate scope of the reaction shows that the synthesis of 2-methoxy-
5-arylphenols is a moderate-high yielding process (50-75%) without need for further optimization 
for cycloadducts containing electron-poor, rich, and heteroaromatic substituents (2.43b-g). We 
were also curious how the reaction would respond to non-aromatic containing substituents such as 
for cycloadducts made from 3-butyne-2-one (Scheme 2.10B, 2.44). In this case, the reaction yield 
was low for the formation of 2.45 (10%), and also lead to 2.46 (28%) which could arise through 
tautomerization-based rearomatization rather than deacylation. It is possible that the methyl ketone 
in this instance serves as an internal base to facilitate the tautomerization. In order to further 
confirm the mechanistic hypothesis proposed in scheme 2.10A we ran the reaction of 2.36c and 
boron trichloride in deuterated chloroform and monitored the reaction by 1H NMR before workup. 
The 1H NMR proved to contain acetyl-chloride, presumably from the chloride ion trapping the 


















































































2.45, 10% 2.46, 28%
Scheme 2.10A: Mechanistic hypothesis and substrate scope study for BCl3 mediated 
transformations of oxabicycles to 2-methoxy-5-arylphenols. B: 3-butyn-2-one-derived 
cycloadduct, and products resulting after reaction with BCl3.
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A substrate scope was also completed for the formation of 2-methoxy-4-aryl-6-
methylphenols from the methanesulfonic acid-mediated transformations (Scheme 2.11). The 
reaction was very low yielding (6-41%, 2.49a-c, and 2.49e-g) and in the case of electron poor 
aromatic substituents (2.49d) resulted in <5% yield of product formation. This is however 
consistent with the mechanistic hypothesis where you would expect more electron withdrawing 
substrates (2.49d) and more sterically hindered substrates (2.49f) to be lower yielding. 
Optimization attempts by using alternative acids such as triflic acid, boron trifluoride etherate, and 
amberlyst all resulted in similar yields (result not shown). These studies represent a new synthetic 
pathway for oxidopyrylium cycloadducts, particularly maltol-derived ylides. As of this report, 
oxidopyrylium ylides have now been known to form 5-membered, 6-membered, and 7-membered 
aromatic structures.19 
2.8. Conclusions 
The implications of the mechanism studies explain that while both allomaltol-derived and 
maltol-derived oxidopyrylium ylides form dimers from a [5 + 3] cycloaddition, and in the case of 
maltol-derived ylide (2.32) two regioisomeric dimers are formed (2.33 and 2.34), energy barriers 
for this formation are higher than for the conversion of 2.21 to 2.19. Instead of the dimer reacting 



































2.49b, R = Me, 25%
2.49c, R = OMe, 35%
2.49d, R = CF3, < 5%
2.49e, R = Cl, 28%
2.49f, 6% 2.49g, 22%
Scheme 2.11: Mechanistic hypothesis for MsOH mediated ring contractions of cycloadducts
and substrate scope study.
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whereby dimer conversion to cycloaddition products proceeds through cycloreversion of the 
dimers to oxidopyrylium ylides and thus in the presence of reactive dipolarophiles will form the 
more thermodynamically stable oxabicyclic products at varying rates. Kinetics from the reaction 
from dimer 2.19 and DMAD (2.35a) are consistent with a mechanism wherein the transition state 
energy for [5 + 3] cycloreversion/dimerization is lower than that of the [5 + 2] cycloaddition 
reaction, and that from 2.33/2.34 consistent with one where the transition state for [5 + 3] 
cycloreversion/dimerization is higher in energy than the [5 + 2] cycloaddition step. DFT 
calculations were fully consistent with these trends. The DFT studies indicate that these energy 
differences are the result of steric interactions in the transition state towards both dimer 2.33 and 
2.34, which also alters the dimerization mechanism for these. The implications of these more 
broadly show that by positioning groups ortho to the oxide, the transition state barrier towards 
dimerization can increase and improve the potential of successfully trapping the ylide with a 
dipolarophile resulting in an extremely efficient method for rapid access to complex cycloadducts. 
In addition, the use of isolated dimer and the evidence that it can undergo cycloreversion to yield 
the reactive ylide also offers numerous synthetic benefits.  
 The synthetic studies show oxidopyrylium cycloadducts derived from maltol and aryl 
acetylenes can undergo an acid-promoted ring-contraction/aromatization cascade process to form 
aryl-substituted guaiacol derivatives. The reaction is regiodivergent depending on the nature of the 
acid and the resulting stability and reactivity of the transition state. Given the interest in 
oxidopyrylium cycloaddition reaction, these studies represent a new utility for oxidopyrylium 
cycloadducts that could find usage in natural product synthesis and medicinal chemistry-based 
pursuits. Overall, this work assessed 3-hydroxy-4-pyrone-derived oxidopyrylium cycloaddition 
chemistry by assessing the mechanistic implications of the highly reactive ylide intermediates in 
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their [5 + 3] dimerizations and [5 + 2] cycloadditions with dipolarophiles. In particular, the novel 
use of maltol-derived ylides in their cycloadditions was assessed as well as understanding the 
synthetic utility of their cycloadducts in acid-mediated transformations to guaiacol derivatives. 
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2.10. Supplementary Experimental Details 
 
 Dr. Edyta and Alexander Greer performed DFT calculations for computational modeling 
data. Dr. William Hirsch obtained X-ray crystal structures of dimers. All of the experimental 
details presented below and in further detail may also be found in the supporting information for 
the publications on which this chapter is based. S1,S2  
2.10.1. General Information  
All starting materials and reagents were purchased from commercially available sources 
and used without further purification. 1H NMR shifts are measured using the solvent residual peak 
as the internal standard (CDCl3 δ 7.26, CD3CN δ 1.93), and reported as follows: chemical shift, 
multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd =doublet of doublet, q = 
quartet, m = multiplet), coupling constant (Hz), and integration. 13C NMR shifts are measured 
using the solvent residual peak as the internal standard (CDCl3 δ 77.2, CD3CN δ 1.3 and δ 117.7), 
and reported as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong 
(s), medium (m), and weak (w). Microwave reactions were performed via the Biotage Initiator 2.5. 
Purification via normal phase column chromatography was performed on the Biotage Isolera 
Prime, with Biotage SNAP 10 g or 25 g cartridges or SiliCycle SiliaSep 12 g or 25 g cartridges, in 
a solvent system of ethyl acetate (EtOAc) in hexane. Column gradients are measured in terms of 
column volumes (CV). Mass spectra were recorded on a spectrometer by the electrospray 




2.10.2. Synthesis and Characterization of Maltol-Derived Oxidopyrylium Salt. 3-hydroxy- 4-
methoxy-2-methylpyrylium trifluoromethanesulfonate (2.31). To a solution of maltol (5g, 
0.040 mol) in CH2Cl2 (10 mL) was added methyl trifluoromethanesulfonate (6.5 
mL, 0.059 mol). The reaction was allowed to stir at reflux for 4 h, cooled to 
ambient temperature, and then evaporated under reduced pressure to yield 2.31 as solid white 
crystals (6.5 g, 54% yield), with a melting point range of 99-102 °C. IR (thin film, KBr): 3088 
(w), 1634 (s), 1554 (w), 1497 (m), 1438 (w), 1258 (b), 1164 (s), 1069 (w), 1033 (s), 962 (w), 903 
(w), 827 (w), 750 (b), 636 (s) cm-1. 1H NMR (400 MHz, CD3CN) δ 8.80 (d, J = 5.2 Hz, 1H), 7.60 
(d, J = 5.2 Hz, 1H), 4.31 (s, 3H), 2.68 (s, 3H). 13C {1H} NMR (101 MHz, CD3CN) δ 168.8, 166.4, 
161.2, 142.9, 108.5, 60.7, 16.3.  
2.10.3. Synthesis and Characterization of Maltol-Derived Oxidopyrylium Dimers (2.33) and 
(2.34). In a round bottom flask, triflate salt 2.31 (0.1 g, 0.35 mmol, 1 eq), was suspended in CH2Cl2 
(3 mL, 0.1 M). Triethylamine (96 µL, 0.69 mmol, 2 eq) was slowly added to the reaction mixture, 
at which time the solid slowly dissolved.  The reaction mixture was allowed to stir for 2 h at room 
temperature, and was then quenched with saturated aqueous ammonium chloride (5 mL).  The 
organic layer was isolated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL).  
Combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. 
The crude material was purified by chromatography (Biotage Isolera Prime, SNAP 12 g silica gel, 
18 cm x 1.8 cm, solvent gradient: 0-25% EtOAc in hexanes (500 mL). Two products were 
separated and product fractions were concentrated to yield 2.33 (22 mg, 0.079, 45% yield) and 









diene-10,12-dione (2.33). Mp: 129-132 °C. Rf = 0.14 in 20 % ethyl acetate in hexanes. IR (ATR, 
ZnSe) 3090 (w), 3002 (w), 2941 (br), 2834 (br), 1742 (s), 1699 (s), 1626 (s), 
1455 (w), 1358 (m), 1258 (m), 1170 (s), 1139 (s), 1066 (s), 1036 (m), 914 (m), 
841 (w), 789 (w).  1H NMR (400 MHz, CDCl3) δ 6.67 (d, J = 5.9 Hz, 1H), 6.01 
(d, J = 5.1 Hz, 1H), 5.02 (d, J = 5.9 Hz, 1H), 4.49 (d, J = 5.1 Hz, 1H), 3.63 (s, 3H), 3.49 (s, 3H), 
1.55 (s, 3H), 1.25 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 199.5, 188.8, 149.9, 148.2, 113.0, 
100.5, 92.4, 87.6, 86.3, 77.4, 55.5, 54.1, 17.3, 14.7. HRMS (ESI-TOF) m/z: [M+H]+ calc’d for 
C7H9O3+ : 141.0473 Found: 141.0561.  
(±)-(1R,2R,6R,7R)-6,9-dimethoxy-2,7-dimethyl-3,11-dioxatricyclo[5.3.1.12,6]dodeca-4,9-
diene-8,12-dione (2.34). Mp: 159-159 °C.  Rf = 0.14 in 25 % ethyl acetate. IR (ATR, ZnSe) 3090  
(w), 3002 (w), 2941 (br), 2834 (br), 1742 (s), 1699 (s), 1626 (s), 1455 (w), 1358 
(m), 1258 (m), 1170 (s), 1139 (s), 1066 (s), 1036 (m), 914 (m), 841 (w), 789 (w).  
1H NMR (400 MHz, CDCl3) δ 6.69 (d, J = 6.0 Hz, 1H), 5.64 (d, J = 5.2 Hz, 1H), 
4.92 (d, J = 6.0 Hz, 1H), 4.74 (d, J = 5.2 Hz, 1H), 3.60 (s, 3H), 3.43 (s, 3H), 1.45 (s, 3H), 1.39 (s, 
3H). 13C{1H} NMR (101 MHz, CDCl3) δ 199.3, 188.5, 150.7, 148.3, 109.0, 98.3, 89.7, 87.8, 86.0, 
80.0, 55.4, 54.5, 17.1, 17.0. HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C7H9O3+ : 141.0473 
Found: 141.0838. Stereochemistry of 2.33 and 2.34 were determined by X-ray crystal analysis.  
See X-ray section, below. 
2.10.4. Synthesis of New Oxidopyrylium [5 + 2] Cycloadducts for Characterization. 
Cycloadducts 2.20, 2.36e and 2.36f were synthesized previously.S3 Compounds 2.35, 2.36a, 2.36b, 
2.36c, and 2.36d were synthesized as follows to provide characterization data in support of 1H 



















dicarboxylate (2.35). To a solution of 2.33/2.34 (20 mg, 0.071 mmol, 1 eq) in CDCl3 (1 mL, 0.9 
M) was added dimethyl acetylenedicarboxylate (2.37a, 100 µL, 0.81 mmol, 11 
eq). The reaction was subjected to microwave irradiation at 150 °C for 2 h, and 
immediately purified by chromatography (Biotage Isolera Prime, SiliCycle 
SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). 
Product fractions were concentrated en vacuo to yield 2.35 as a pale, yellow oil (38 mg, 95% 
yield). Rf = 0.53 in 25% ethyl acetate. IR (thin film, KBr): 2956 (w), 2843 (w), 1716 (s), 1654 
(w), 1614 (m), 1438 (m), 1379 (w), 1281 (b), 1146 (w), 1069 (s), 1005 (m), 933 (w), 902 (w), 878 
(w), 847 (w), 812 (w), 787 (w), 766 (w), 700 (w), 6309 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 
6.15 (d, J = 4.9 Hz, 1H), 5.39 (d, J = 4.9 Hz, 1H), 3.79 (d, J = 6.4 Hz, 6H), 3.56 (s, 3H), 1.59 (s, 
3H). 13C{1H} NMR (101 MHz, CDCl3) δ 188.2, 163.1, 162.1, 146.5, 146.4, 143.1, 114.4, 94.0, 
78.2, 55.1, 52.8. 52.8, 16.2. HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C13H15O7+ : 283.0812 
Found: 283.0817. 
(±)-(5R,9S)-7-methoxy-5-methyl-2-phenyl-1H,5H-5,9-epoxy[1,2,4]triazolo[1,2-
a][1,2]diazepine-1,3,6(2H,9H)-trione (2.36a). To a solution of 2.31 (50 mg, 0.17 mmol, 1 eq) 
and 4-Phenyl-1,2,4-triazole-3,5-dione (2.37b, 60 mg, 0.344 mmol, 2 eq) in CD3CN 
(600 µL, 0.3 M) was added N,N-diisopropylaniline (29 µL, 0.21 mmol, 1.2 eq). 
The reaction stirred for 5 minutes and was then immediately purified by 
chromatography (Biotage Isolera Prime, SiliCycle, SiliaSep 25 g silica gel column, 40-63 µm 60 
Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were concentrated en 
vacuo to yield 2.36a as a white solid (39 mg, 72% yield). Mp: 65-70 °C. Rf = 0.50 in 25% in ethyl 















(w), 1148 (w), 1075 (m), 778 (w), 690 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.38 (m, 
5H), 6.34 (d, J = 5.0 Hz, 1H), 6.11 (d, J = 5.0 Hz, 1H), 3.70 (s, 3H), 1.96 (s, 3H).13C{1H} NMR 
(101 MHz, CDCl3) δ 182.2, 156.5, 154.87, 150.9, 130.9, 129.5, 129.1, 125.6, 109.8, 96.8, 83.4, 
55.9, 15.2. HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C15H14N3O5+ : 316.0928 Found: 316.0928. 
Synthesis of (5R,9S)-7-methoxy-9-methyl-2-phenyl-1H,5H-5,9-epoxy[1,2,4]triazolo[1,2-
a][1,2]diazepine-1,3,6(2H,9H)-trione (2.36d) in the presence of excess salt*: To a mixture of 
oxidopyrylium salt 2.2 (20 mg, 0.069 mmol) and 4-phenyl-1,2,4-triazoline-3,5-
dione (2.37b, 8 mg 0.046 mmol) in DCM (1 mL, 0.05 M) was added 
triethylamine (12 µL, 0.086 mmol). The reaction was stirred for 5 minutes at 
room temperature and subsequently washed with aqueous ammonium chloride 
(3 x 3 mL). The organic layer was isolated and the aqueous layer was extracted with CH2Cl2 (3 x 
5 mL). Combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure to yield a mixture of dimer 2.19, cycloadduct 2.36d, and PTAD (2.35b). 2.36d is unstable 
to chromatography and attempts at crystallization were unsuccessful.  It was thus characterized as 
a mixture of the three.  1H NMR (400 MHz, CD3CN) δ 7.59 – 7.35 (m, Ar)*, 6.28 (s, 1H), 5.86 
(s,1H), 3.66 (s, 3H), 2.07 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 182.5, 157.3, 155.8, 150.5, 
125-135 (Ar),* 116.6, 89.9, 56.5, 55.3, 21.1. *Aromatic regions undefined due to presence of 
PTAD overlapping in the aromatic region. HRMS (ESI-TOF) m/z: [M+H]+ calc’d for 












carboxylate (2.36b). To a solution of 2.34 (25 mg, 0.0893mmol, 1 eq) in CDCl3 (1 mL, 0.9M) 
was added methylpropiolate (2.37c, 80 µL, 0.893 mmol, 10 eq). The reaction 
was subjected to microwave irradiation at 100 °C for 2 h and then purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel 
column, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions 
were concentrated en vacuo to yield 2.36b as a yellow oil (24 mg, 60% yield). Rf = 0.20 in 25% 
ethyl acetate. IR (thin film, KBr): 3448 (br), 2956 (w), 2358 (w), 1716 (s), 1654 (w), 1614 (m), 
1438 (m), 1336 (m), 1379 (w), 1227 (w) 1281 (br), 1146 (w), 1069 (s), 1033 (m), 933 (w), 902 
(w), 878 (w), 847 (w), 812 (w) cm-1.  1H NMR (400 MHz, CDCl3) δ 6.88 (s, 1H), 6.22 (d, J = 4.9 
Hz, 1H), 5.41 (d, J = 4.9 Hz, 1H), 3.81 (s, 3H), 3.57 (s, 3H), 1.59 (s, 3H). 13C{1H} NMR (101 
MHz, CDCl3) δ 190.6, 163.1, 148.2, 146.5, 142.2, 115.6, 93.5, 78.1, 55.0, 52.4, 17.1. HRMS 
(ESI-TOF) m/z: [M+H]+ calc’d for C11H13O5+ : 225.0757 Found: 225.0751. 
(±)-(1S,5S)-3-methoxy-1-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.36c). To 
a solution of 2.34 (25 mg, 0.089 mmol, 1 eq) in CDCl3 (1 mL, 0.9 M) was added 
phenylacetylene (2.37d, 100 µL, 0.91 mmol, 11 eq). The reaction was subjected 
to microwave irradiation at 120 °C for 8 h and then purified by chromatography 
(Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel column, 40-63 µm 60 Å, solvent gradient: 
0-25% EtOAc in hexanes (500 mL)). Product fractions were concentrated en vacuo to yield 2.36c 
as a yellow oil (7 mg, 16% yield).  Rf = 0.13 in 25 % in ethyl acetate. IR (thin film, KBr): 3446 
(br), 2933 (w), 1705 (s), 1614 (m), 1446 (w), 1343 (w), 1242 (w), 1063 (br), 905 (w), 852 (w), 691 
(w), 649 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.35 (m, 5H), 6.30 (d, J = 4.9 Hz, 1H), 












δ 191.6, 155.8, 147.4, 131.9, 129.4, 129.1, 126.0, 124.0, 114.9, 93.1, 79.1, 55.0, 17.6. HRMS 
(ESI-TOF) m/z: [M+H]+ calc’d for C15H15O3+ : 243.1016 Found: 243.1001. 
 
2.10.5. Evaluation of Product versus Dimer Upon Full Conversion of Oxidopyrylium Salt.	In 
a small vial, salt (2.2) or 2.31) (5mg, 0.0172 mmol, 1 eq), alkyne (2.37a-d) (0.172 mmol, 10 eq) 
in 600 µL of CD3CN was added N,N-diisopropylaniline (4 µL, 0.0207 mmol, 1.2 eq). The reaction 
was monitored over time by 1H NMR, and yields were calculated using 1H NMR integration based 
upon known amount of 3,5-ditertbutyltoluene standard in the reaction mixture.  
2.10.6. Rate data.  All rate studies were conducted in Wilmad® low pressure/vacuum NMR tube 
where concentrations of substrates were determined via known amount of added internal NMR 
standard, 3,5-Di-tert-butyltoluene. All experiments were run at least twice to obtain consistent data 
sets. 
General procedure for excess of 2.37a with dimers 2.19, 2.33, and 2.34 separately:	To dimer 
(2.19, 2.33, or 2.34) (3 mg, 0.01 mmol) in 600 µL of deuterated toluene was added 2.37a (26.5 
µL, 0.2 mmol, 20 eq). The reaction was heated in an oil bath (100 °C for dimers 2.33 and 2.34, 70 
°C for dimer 2.19 and monitored to near completion via internal NMR standard (3,5-di-tert-
butyltoluene). 
General procedure for excess of dimers 2.19, 2.33, and 2.34 separately with 2.37a: To dimer 
(2.19, 2.33, or 2.34) (15 mg, 0.05 mmol) in 600 µL of deuterated toluene was added 2.37a (1.3 
µL, 0.01 mmol). The reaction was heated in an oil bath (100 °C for dimers 2.33 and 2.34, 70 °C 
for dimer 2.19) and monitored to near completion via internal NMR standard (3,5-di-tert-
butyltoluene).  
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Table S1: Decrease in concentration of dimer (2.19) and formation of product (2.20) 





























































Table S2: Decrease in concentration of DMAD (2.35a) over time when heated in the 
presence of an excess of dimer (2.19). 
 
 












































Table S3: Decrease in concentration of dimer (2.33) and formation of product (2.35) 































































Table S4: Decrease in concentration of DMAD (2.37a) over time when heated in the 


















Figure S4: Graph of [DMAD (2.37a)] vs time from Table S4. 
  
 




















































Table S5: Decrease in concentration of dimer (2.34) and formation of product (2.35) 






























































Table S6: Decrease in concentration of DMAD (2.37a) over time when heated in the 




























































2.10.7. Computational Methods. Optimizations, frequency calculations, the intrinsic reaction 
coordinate calculations were performed with Gaussian 09 (revision D.01)S4 at the B3LYP/6-
31G(d,p) level of theoryS5 and visualized with Gaussview 5.0.S6 These calculations yielded results 
in reasonably good agreement with experiment. The energetics are reported as the thermal 
enthalpies. For the potential energy surface (PES), frequency calculations established the nature 
of the stationary point obtained. Vibrational analyses showed that TS-1—TS-4 species were 
transition structures, while 2.21, 2.32, 2.19, 2.33, and 2.34 minima.  The intrinsic reaction 
coordinateS7 (IRC)S calculations were used to verify the transition structures TS-1—TS-4. 
Energies and Cartesian coordinates can be found in the publications supplementary information.S1 
 
2.10.8. X-Ray. The structures of 2.19, 2.33, and 2.34 are the first to be determined for these 
tricyclic heterocycles, and they confirm the proposed structures. Crystals were grown using vapor 
diffusion technique, using minimal ethyl acetate to solubilize dimers and hexanes as the outer 
solvent.  The crystals of 2.33 and 2.34 appeared to be split crystals, most likely with more than 
two domains, giving rise to relatively high residuals due to overlapping peaks and in addition 2.33 
was not strongly diffracting. The X-ray intensity data were measured on a Bruker Smart Breeze 
CCD system equipped with a graphite monochromator at 100(2) K, cooled by an Oxford 
Cryosystems 700 Series Cryostream. A total of 1464 frames were collected and were integrated 
with the Bruker SAINT software package, using a narrow-frame algorithm. Data were corrected 
for absorption effects using the multi-scan method (SADABS or TWINABS). The structures were 
solved and refined using the Bruker SHELXTL Software Package. All data and methods may be 
found in the cif files included in the Supporting Information. Briefly, refinement of 2.19 was 
routine and 2.33 was refined as a 2-component twin. Compound 2.34 had to be refined as a 2-
	 60	
component twin but the second domain refined to just 2%, and it also exhibited a ~1:1 disorder for 
molecule 2 of the two in the asymmetric unit, for one methoxy methyl and one methyl group. 
 
Cambridge Crystallographic Data Centre deposition numbers for 2.19, 2.33, and 2.34:  CCDC 
1935838, 1935839, and 1935840. The data can be obtained free from Cambridge Crystallographic 





























Figure S7. (a) Mercury plots with complete numbering of atoms for 2.19 (a), 2.33 (b), and 2.34 
(c). The structure for 2.19 is inverted from that given by the coordinates for the asymmetric unit 
in P21/n, in order to allow direct comparison to 2.33 and 2.34. 
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2.10.9. Synthesis of maltol-derived aryl substituted oxabicycles. 
 (1S,5S)-3-methoxy-1-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.36c)*: 
 
To a solution of 2.33/2.34 (250 mg, 0.89 mmol, 1 eq) was added 
phenylacetylene (966 µL, 8.9 mmol, 10 equiv). The reaction was subjected to 
microwave irradiation at 120 °C for 3 h, and immediately purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-
63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions were 
concentrated en vacuo to yield 2.36c as a yellow oil (107.7 mg, 25% yield).  
*Characterization procedure altered from previous publication. S1, S2 
 
 (1S,5S)-3-methoxy-1-methyl-6-(p-tolyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.40a): 
 
To a solution of 2.33/2.34 (50 mg, 0.18 mmol, 1 eq) was added 4-
ethynyltoluene (228 µL, 1.8 mmol, 10 equiv). The reaction was subjected to 
microwave irradiation at 120 °C for 2 h, and immediately purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-
63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions were 
concentrated en vacuo to yield 2.40a as a yellow oil (36 mg, 39% yield). Rf = 0.4 in 20% ethyl 
acetate. IR (thin film, KBr): 2934 (br), 2361 (m), 1707 (s), 1613 (m), 1511 (m), 1450 (w), 1375 
(m), 1342 (m), 1295 (m), 1249 (m), 1180 (m), 1133 (m), 1063 (m), 935 (m), 906 (m), 852 (w), 
804 (w), 764 (w), 724 (w), 674 (w) cm -1. 1H NMR (400 MHz, CDCl3) δ 7.29 – 7.25 (m, 7H), 
7.20 (d, J = 8.0 Hz, 6H), 6.28 (d, J = 4.9 Hz, 3H), 6.20 (s, 3H), 5.56 (d, J = 4.8 Hz, 3H), 3.54 (s, 











(s), 139.6 (s), 129.8 (s), 129.1 (s), 126.0 (s), 122.7 (s), 115.0 (s), 93.0 (s), 79.1 (s), 54.9 (s), 21.5 





To a solution of 2.33/2.34 (50 mg, 0.18 mmol, 1 eq) was added 4-
ethynylanisole (237 µL, 1.8 mmol, 10 equiv). The reaction was subjected to 
microwave irradiation at 120 °C for 2 h, and immediately purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-
63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions were 
concentrated en vacuo to yield 2.40b as a yellow oil (39 mg, 40% yield). Rf = 0.25 in 20% ethyl 
acetate. IR (thin film, KBr): 2935 (br), 2838 (m), 1707 (s), 1610 (m), 1511 (m), 1462 (m), 1030 
(m), 935 (m), 906 (m), 839 (w), 795 (w), 70 (m), 590 (m) cm-1. 1H NMR (400 MHz, CDCl3) δ 
7.31 (d, J = 8.9 Hz, 2H), 6.96 – 6.85 (m, 2H), 6.27 (d, J = 4.9 Hz, 1H), 6.10 (s, 1H), 5.53 (d, J = 
4.8 Hz, 1H), 3.83 (s, 3H), 3.54 (s, 3H), 1.62 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 191.6 (s), 
160.6 (s), 155.4 (s), 147.5 (s), 127.5 (s), 124.7 (s), 121.1 (s), 114.8 (s), 114.5 (s), 93.0 (s), 79.1 (s), 







To a solution of 2.33/2.34 (50 mg, 0.18 mmol, 1 eq) was added 4-ethynyl-
a,a,a-tifluorotoluene (293 µL, 1.8 mmol, 10 equiv). The reaction was 
subjected to microwave irradiation at 120 °C for 2 h, and immediately 












silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions 
were concentrated en vacuo to yield 2.40c as a yellow oil (33 mg, 30% yield). Rf = 0.32 in 20% 
ethyl acetate. IR (thin film, KBr): 2930 (br), 2361 (m), 1709 (s), 1614 (m), 1455 (m), 1412 (m), 
1377 (m), 1325 (m), 1250 (m), 1167 (m), 1124 (m), 1068 (m), 1016 (m), 935 (m), 907 (m), 850 
(w), 815 (m), 786 (m), 741 (m), 718 (m), 668 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J 
= 8.2 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 6.42 (s, 1H), 6.28 (d, J = 4.9 Hz, 1H), 5.58 (d, J = 4.8 Hz, 
1H), 3.56 (s, 3H), 1.64 (s, 3H). 13C {1H} NMR (101 MHz, CDCl3) δ 191.1 (s), 154.6 (s), 147.5 
(s), 135.2 (s), 131.0 (q, J = 33.3 Hz), 127.1 (s), 126.2 (s), 126.1 (s) (q, J = 4 Hz), 123.9 (q, J = 
272.7 Hz), 114.4 (s), 93.2 (s), 79.0 (s), 55.0 (s), 17.5 (s). HRMS (ESI-TOF) m/z: [M+H]+ calc’d 





To a solution of 2.33/2.34 (50 mg, 0.18 mmol, 1 eq) in CDCl3 (1 mL, 0.4 M) 
was added 1-chloro-4-ethynylbenzene (323 mg, 2.4 mmol, 6.7 equiv). The 
reaction was subjected to microwave irradiation at 120 °C for 2 h, and 
immediately purified by chromatography (Biotage Isolera Prime, SiliCycle 
SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in 
hexanes (500 mL)). Product fractions were concentrated en vacuo to yield 2.40d as a yellow oil 
(30 mg, 30% yield). Rf = 0.16 in 20% ethyl acetate. IR (thin film, KBr): 3453 (br), 2940 (w), 
1708 (s), 1615 (m), 1441 (w), 1369 (w), 1305 (w), 1241 (w), 1062 (m), 934 (w), 907 (w), 917 (m), 
863 (w), 836 (w), 723 (s) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.8 Hz, 2H), 7.29 (d, 
J = 8.7 Hz, 2H), 6.28 – 6.24 (m, 2H), 5.53 (d, J = 4.8 Hz, 1H), 3.55 (s, 3H), 1.62 (s, 3H). 13C NMR 







(s), 114.5 (s), 93.1 (s), 79.0 (s), 55.0 (s), 17.5 (s). HRMS (ESI-TOF) m/z: [M+H]+ calc’d for 





To a solution of 2.33/2.34 (175 mg, 0.63 mmol, 1 eq) was added 1-
ethynylnapthalene (887 µL, 6.3 mmol, 10 equiv). The reaction was 
subjected to microwave irradiation at 120 °C for 2 h, and immediately 
purified by chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 
g silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product 
fractions were concentrated en vacuo to yield 2.40e as an orange oil (106 mg, 29% yield).Rf = 0.19 
in 20% ethyl acetate. IR (thin film, KBr): 3057 (w), 2934 (w), 1707 (s), 1614 (m), 1507 (w), 1450 
(w), 1395 (w), 1342 (m), 1240 (m), 1139 (m), 1062 (s), 930 (m), 904 (w), 853 (w), 799 (m), 776 
(m), 723 (m) cm-1. 1H NMR (400 MHz, CDCl3) δ 8.09 (dd, J = 6.2, 3.5 Hz, 1H), 7.92 – 7.80 (m, 
2H), 7.58 – 7.51 (m, 2H), 7.47 (dd, J = 8.2, 7.2 Hz, 1H), 7.32 (dd, J = 7.1, 1.1 Hz, 1H), 6.27 (s, 
1H), 6.22 (d, J = 4.9 Hz, 1H), 5.54 (d, J = 4.9 Hz, 1H), 3.58 (s, 3H), 1.73 (s, 3H). 13C {1H} NMR 
(101 MHz, CDCl3) δ 191.7 (s), 155.1 (s), 147.2 (s), 133.9 (s), 131.0 (s), 130.7 (s), 129.4 (s), 129.1 
(s), 128.8 (s), 127.0 (s), 126.5 (s), 125.2 (s), 125.1 (s), 124.8 (s), 115.8 (s), 93.4 (s), 82.1 (s), 55.1 














To a solution of 2.33/2.34 (100 mg, 0.36 mmol, 1 eq) in CDCl3 (1 mL, 0.4 M) 
was added 3-ethynylthiophene (354 µL, 3.6 mmol, 10 equiv). The reaction was 
subjected to microwave irradiation at 120 °C for 2 h, and immediately purified 
by chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-
63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions were 
concentrated en vacuo to yield 2.40f as a yellow oil (46 mg, 26% yield). Rf = 0.22 in 20% ethyl 
acetate. IR (thin film, KBr): 3096 (w), 2934 (m), 1704 (s), 1612 (m), 1450 (m), 1374 (m), 1268 
(m), 1244 (m), 1150 (m), 1128 (m), 1062 (m), 917 (m), 857 (w), 845 (w), 777 (m), 713 (m) cm-1. 
1H NMR (400 MHz, CDCl3) δ 7.37 (dd, J = 5.0, 2.9 Hz, 1H), 7.24 – 7.17 (m, 2H), 6.26 (d, J = 
4.9 Hz, 1H), 6.07 (s, 1H), 5.47 (d, J = 4.9 Hz, 1H), 3.55 (s, 3H), 1.62 (s, 3H). 13C {1H} NMR (101 
MHz, CDCl3) δ 191.4 (s), 150.8 (s), 127.3 (s), 126.0 (s), 122.6 (s), 114.7 (s), 92.8 (s), 79.5 (s), 




To a solution of 2.33/2.34 (100 mg, 0.36 mmol, 1 eq) in CDCl3 (700 µL, 0.5 M) 
was added 3-butyn-2-one (281 µL, 3.6 mmol, 10 equiv). The reaction was 
subjected to microwave irradiation at 120 °C for 2 h, and immediately purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 
µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions were 
concentrated en vacuo to yield 2.44 as a yellow oil (58 mg, 39% yield). Rf = 0.13 in 20% ethyl 













(w), 1403 (w), 1376 (w), 1344 (w), 1249 (m), 1064 (s), 1013 (m), 936 (w), 906 (w), 840 (w), 814 
(w), 784 (m) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.79 (s, 1H), 6.23 (d, J = 4.9 Hz, 1H), 5.43 (d, 
J = 4.9 Hz, 1H), 3.55 (s, 3H), 2.37 (s, 3H), 1.62 (s, 3H). 13C {1H} NMR (101 MHz, CDCl3) δ 
194.0 (s), 190.7 (s), 155.6 (s), 146.4 (s), 141.8 (s), 115.9 (s), 93.7 (s), 78.0 (s), 55.0 (s), 27.1 (s), 
17.2 (s). HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C11H13O4+: 209.0808. Found: 209.0783. 
 
2.10.10. Synthesis of 2-methoxy-5-arylphenols 
4-methoxy-[1,1'-biphenyl]-3-ol (2.43a): 
To a solution of 2.36c (9 mg, 0.04 mmol, 1 eq) in CH2Cl2  (0.5 mL, 0.07 M) at 0°C, a 
1M solution of boron trichloride in CH2Cl2 (148 µL, 0.15 mmol, 4 eq) was added. The 
reaction stirred at room temp for 15 minutes, at which point the reaction was quenched 
with pH 5 phosphate buffer to a final pH of 3. The reaction mixture was then extracted 
with DCM (5 x 10 mL). The combined organics were dried over Na2SO4 and concentrated en 
vacuo to a yellow oil. The crude product was purified by chromatography (Biotage Isolera Prime, 
SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 
mL). Product fractions were concentrated en vacuo to yield 2.43a as a clear oil (6 mg, 71% yield). 
1H NMR (400 MHz, CDCl3) δ 7.55 (dd, J = 8.3, 1.2 Hz, 2H), 7.40 (dd, J = 10.8, 4.5 Hz, 2H), 7.31 
(dt, J = 9.2, 4.3 Hz, 1H), 7.20 (d, J = 2.2 Hz, 1H), 7.09 (dd, J = 8.3, 2.2 Hz, 1H), 6.92 (d, J = 8.4 
Hz, 1H), 3.94 (s, 3H).  















To a solution of 2.40a (27 mg, 0.11 mmol, 1 eq) in CH2Cl2 (1.0 mL, 0.1 M) at 0 °C, 
a 1M solution of boron trichloride in CH2Cl2 (420 µL, 0.42 mmol, 4 eq) was added. 
The reaction stirred at room temp for 15 minutes, at which point the reaction was 
quenched with pH 5 phosphate buffer to a final pH of 3. The reaction mixture was 
then extracted with DCM (5 x 10 mL). The combined organics were dried over 
Na2SO4 and concentrated en vacuo to a yellow oil. The crude product was purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent 
gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were concentrated en vacuo to 
yield 5b as a white solid (12 mg, 51% yield). Mp: 120-122 °C. Rf = 0.35 in 20% ethyl acetate. IR 
(thin film, KBr): 3536 (br), 3332 (br), 2966 (m), 2934 (m), 1589 (m), 1506 (m), 1441 (m), 2011 
(m), 1301 (m), 1265 (m), 1213 (m), 1193 (m), 1137 (m), 1040 (m), 1016 (m), 989 (m), 871 (w), 
823 (w), 801 (m), 737 (w), 704 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.40 (m, 2H), 7.22 
(d, J = 7.9 Hz, 2H), 7.18 (d, J = 2.2 Hz, 1H), 7.08 (dd, J = 8.3, 2.2 Hz, 1H), 6.91 (d, J = 8.3 Hz, 
1H), 5.63 (s, 1H), 3.93 (s, 3H), 2.38 (s, 3H). 13C {1H} NMR (101 MHz, CDCl3) δ 146.1 (s), 145.9 
(s), 138.0 (s), 136.7 (s), 134.9 (s), 129.6 (s), 126.8 (s), 118.7 (s), 113.4 (s), 111.0 (s), 56.2 (s), 21.2 
(s). HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C14H15O2+: 215.1067. Found: 215.0101. 
 
4,4'-dimethoxy-[1,1'-biphenyl]-3-ol (2.43c):  
To a solution of 2.40b (40 mg, 0.15 mmol, 1 eq) in CH2Cl2  (1.5 mL, 0.1 M) at 0 °C, a 
1M solution of boron trichloride in CH2Cl2 (600 µL, 0.60 mmol, 4 eq) was added. The 
reaction stirred at room temp for 15 minutes, at which point the reaction was quenched 
with pH 5 phosphate buffer to a final pH of 3. The reaction mixture was then extracted 








concentrated en vacuo to a yellow oil. The crude product was purified by chromatography (Biotage 
Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc 
in hexanes (500 mL). Product fractions were concentrated en vacuo to yield 2.43c as a yellow solid 
(29 mg, 75% yield). Mp: 136-139 °C. (75%).: Rf = 0.25 in 20% ethyl acetate. IR (thin film, KBr): 
2964 (br), 2838 (m), 1505 (m), 1440 (m), 1279 (m), 1246 (m), 1183 (m), 1042 (m), 1014 (m), 835 
(w), 801 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.43 (m, 2H), 7.15 (d, J = 2.2 Hz, 1H), 
7.04 (dd, J = 8.3, 2.2 Hz, 1H), 6.98 – 6.92 (m, 2H), 6.90 (d, J = 8.3 Hz, 1H), 3.92 (s, 3H), 3.84 (s, 
3H). 13C {1H} NMR (101 MHz, CDCl3) δ 158.9 (s), 145.9 (s), 145.8 (s), 134.6 (s), 133.5 (s), 
127.9 (s), 118.4 (s), 114.3 (s), 113.2 (s), 111.1 (s), 56.2 (s), 55.5 (s). HRMS (ESI-TOF) m/z: 
[M+H]+ calc’d for C14H15O3+: 231.1016. Found: 231.0992. 
 
4-methoxy-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-ol (2.43d): 
To a solution of 2.40c (40 mg, 0.13 mmol, 1eq) in CH2Cl2  (1.3 mL, 0.13 M) at 0 °C,  
a 1M solution of boron trichloride in CH2Cl2 (520 µL, 0.52 mmol, 4 eq) was added. 
The reaction stirred at room temp for 15 minutes, at which point the reaction was 
quenched with pH 5 phosphate buffer to a final pH of 3. The reaction mixture was 
then extracted with DCM (5 x 10 mL). The combined organics were dried over 
Na2SO4 and concentrated en vacuo to a yellow oil. The crude product was purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent 
gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were concentrated en vacuo to 
yield 2.43d as a white solid (19 mg, 50% yield) Mp: 113-116 °C (50%). Rf = 0.33 in 20% ethyl 
acetate. IR (thin film, KBr): 3648 (br), 3545 (br), 1610 (m), 1590 (m), 1573 (m), 1457 (m), 1340 
(m), 1289 (m), 1275 (m), 1265 (m), 1206 (m), 1165 (m), 1178 (m), 1141 (m), 1112 (m), 1074 (m), 





7.20 (d, J = 2.2 Hz, 1H), 7.11 (dd, J = 8.3, 2.2 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.69 (s, 1H), 3.95 
(s, 3H). 13C {1H} NMR (101 MHz, CDCl3) δ 147.0 (s), 146.1 (s), 133.3 (s), 129.0 (q, J = 32.3 Hz), 
127.1 (s), 125.8 (q, J = 4.0 Hz), 125.1 (q, J = 392.0 Hz), 119.2 (s), 113.6 (s), 111.1 (s), 56.2 (s). 
HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C14H12F3+O2+: 269.0784. Found: 269.0742. 
 
Synthesis of 4'-chloro-4-methoxy-[1,1'-biphenyl]-3-ol (2.43e): 
 
To a solution of 2.40d (10 mg, 0.04 mmol, 1eq) in CH2Cl2  (283 µL, 0.13 M) at 0 
°C, a 1M solution of boron trichloride in CH2Cl2 (160 µL, 0.16 mmol, 4 eq) was 
added. The reaction stirred at room temp for 15 minutes, at which point the reaction 
was quenched with pH 5 phosphate buffer to a final pH of 3. The reaction mixture 
was then extracted with DCM (5 x 10 mL). The combined organics were dried over 
Na2SO4 and concentrated en vacuo to a yellow oil. The crude product was purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent 
gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were concentrated en vacuo to 
yield 2.43e as a clear oil (4.6 mg, 50% yield). Rf = 0.30 in 20% ethyl acetate. IR (thin film, KBr): 
3338 (br), 1588 (m), 1522 (m), 1488 (s), 1462 (m), 1442 (w), 1323 (w), 1295 (s), 1255 (m), 1232 
(w), 1200 (m), 1136 (m), 1095 (w), 1039 (w), 1016 (m), 897 (w), 833 (w), 802 (m) cm-1. 1H NMR 
(400 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 2H), 7.37 (d, J = 8.7 Hz, 2H), 7.15 (d, J = 2.2 Hz, 1H), 
7.05 (dd, J = 8.3, 2.2 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 5.65 (s, 1H), 3.93 (s, 3H). 13C {1H} NMR 
(101 MHz, CDCl3) δ 146.5 (s), 146.1 (s), 139.4 (s), 133.7 (s), 133.0 (s), 129.0 (s), 128.2 (s), 118.8 
(s), 113.3 (s), 111.1 (s), 56.2 (s). HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C13H12ClO2+: 










Synthesis of 2-methoxy-5-(naphthalen-1-yl) phenol (2.43f): 
 
To a solution of 2.40e (35.3 mg, 0.11 mmol, 1eq) in CH2Cl2 (845 µL, 0.13 M) 
at 0 °C, a 1M solution of boron trichloride in CH2Cl2 (444 µL, 0.44 mmol, 4 
eq) was added. The reaction stirred at room temp for 15 minutes, at which point 
the reaction was quenched with pH 5 phosphate buffer to a final pH of 3. The 
reaction mixture was then extracted with DCM (5 x 10 mL). The combined organics were dried 
over Na2SO4 and concentrated en vacuo to a yellow oil. The crude product was purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent 
gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were concentrated en vacuo to 
yield 2.43f as a clear oil (18.2 mg, 66% yield) Rf = 0.37 in 20% ethyl acetate. IR (thin film, KBr): 
3512 (br), 3045 (w), 2934 (w), 2838 (w), 1581 (m), 1504 (s), 1461 (m), 1440 (m), 1393 (m), 1288 
(s), 1257 (s), 1245 (m), 1213 (m), 1172 (w), 1026 (m), 993 (w), 901 (m), 798 (s), 777 (s), 735 (w) 
cm-1. 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.5 Hz, 2H), 7.92 – 7.87 (m, 2H), 7.84 (d, J = 
8.2 Hz, 2H), 7.54 – 7.39 (m, 9H), 7.11 (d, J = 0.7 Hz, 2H), 6.99 (d, J = 1.5 Hz, 4H), 5.70 (s, 2H), 
3.98 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 146.1 (s), 145.5 (s), 134.0 (s), 134.3 (s), 133.9 (s), 
131.9 (s), 128.4 (s), 127.5 (s), 127.0 (s), 126.3 (s), 126.1 (s), 125.8 (s), 125.5 (s), 122.0 (s), 116.6 













Synthesis of 2-methoxy-5-(thiophen-3-yl) phenol (2.43g):  
 
To a solution of 2.40f (22 mg, 0.09 mmol, 1 eq) in CH2Cl2 (1.0 mL, 0.1 M) at 0 °C, 
a 1M solution of boron trichloride in CH2Cl2 (360 µL, 0.36 mmol, 4 eq) was added. 
The reaction stirred at room temp for 15 minutes, at which point the reaction was 
quenched with pH 5 phosphate buffer to a final pH of 3. The reaction mixture was 
then extracted with DCM (5 x 10 mL). The combined organics were dried over Na2SO4 and 
concentrated en vacuo to a yellow oil. The crude product was purified by chromatography (Biotage 
Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc 
in hexanes (500 mL). Product fractions were concentrated en vacuo to yield 2.43g as a brown solid 
(14 mg, 74% yield).Rf = 0.34 in 20% ethyl acetate. IR (thin film, KBr): 3326 (br), 3103 (m), 2933 
(m), 1586 (m), 1539 (m), 1507 (m), 1462 (m), 1441 (m), 1282 (m), 1251 (m), 1216 (m), 1170 (m), 
1132 (m), 1045 (w), 1018 (w), 867 (m), 848 (m), 779 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 
7.55 (dd, J = 8.3, 1.2 Hz, 2H), 7.41 (dd, J = 8.2, 7.0 Hz, 2H), 7.34 – 7.28 (m, 1H), 7.09 (d, J = 2.2 
Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 5.64 (s, 1H), 3.94 (s, 3H). 13C {1H} NMR (101 MHz, CDCl3) 
δ 146.3 (s), 145.9 (s), 140.9 (s), 135.0 (s), 128.8 (s), 127.0 (s), 126.9 (s), 118.9 (s), 113.5 (s), 111.0 
(s), 56.2 (s). HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C11H11O2S+: 207.0474. 
 
2.10.11. Synthesis and characterization of 2-methoxy-4-aryl-6-methylphenols 
3-methoxy-5-methyl-[1,1'-biphenyl]-4-ol (2.49a):  
 
To a solution of 2.36c (8 mg, 0.03 mmol, 1 eq) in CH2Cl2 (1 mL, 0.03 M) 
methane sulfonic acid (12 µL, 0.13 mmol, 4 eq) was added. The reaction stirred 
at room temp for 30 minutes, at which point the reaction was quenched with 
pH 5 phosphate buffer to a final pH of 3. The reaction mixture was then extracted with DCM (5 x 







oil. The oil was purified by (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 
60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were concentrated 
en vacuo to yield 2.49a as a clear oil (2.7 mg, 41% yield). Rf = 0.595 in 20% ethyl acetate. IR 
(thin film, KBr): 3524 (br), 3031 (br), 2942 (m), 1510 (m), 1486 (m), 1464 (m), 1444 (m), 1318 
(m), 1248 (m), 1203 (m), 1180 (m), 1092 (w), 1072 (w), 760 (w), 698 (w) cm-1. 1H NMR (400 
MHz, CDCl3) δ 7.56 – 7.52 (m, 2H), 7.40 (dd, J = 10.8, 4.5 Hz, 2H), 7.32 – 7.27 (m, 1H), 7.02 – 
6.98 (m, 1H), 6.94 (d, J = 2.0 Hz, 1H), 5.70 (s, 1H), 3.95 (s, 3H), 2.32 (s, 3H). 13C {1H} NMR 
(101 MHz, CDCl3) δ 146.6 (s), 143.5 (s), 141.6 (s), 132.9 (s), 128.8 (s), 127.0 (s), 126.8 (s), 124.2 
(s), 122.2 (s), 107.4 (s), 56.3 (s), 15.7 (s). NMR data consistent with similar molecule, 3-(tert-
butyl)-5-methoxy-[1,1'-biphenyl]-4-ol.S9 HRMS (ESI-TOF) m/z: [M+H]+ calc’d for C14H15O2+: 
215.1067. Found: 215.1060. 
 3-methoxy-4',5-dimethyl-[1,1'-biphenyl]-4-ol (2.49b): 
To a solution of 2.40a (34 mg, 0.13 mmol, 1 eq) in CH2Cl2 4 mL, 0.03 M) 
methane sulfonic acid (40 µL, 0.53 mmol, 4 eq) was added. The reaction 
stirred at room temp for 30 minutes, at which point the reaction was quenched 
with pH 5 phosphate buffer to a final pH of 3. The reaction mixture was then 
extracted with DCM (5 x 10 mL). The combined organics were dried over Na2SO4 and 
concentrated en vacuo to a yellow oil. The oil was purified by (Biotage Isolera Prime, SiliCycle 
SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL). 
Product fractions were concentrated en vacuo to yield 2.49b as a yellow oil (7.5 mg, 25% yield).  
Rf = 0.57. IR (thin film, KBr): 3523 (br), 2919 (br), 1604 (m), 1493 (n), 1463 (m), 1426 (m), 1397 
(m), 1318 (m), 1306 (m), 1249 (m), 1213 (m), 1201 (m), 1179 (m), 1092 (w), 1071 (w), 996 (w), 





J = 7.8 Hz, 2H), 7.00 – 6.94 (m, 1H), 6.92 (d, J = 2.0 Hz, 1H), 5.67 (s, 1H), 3.94 (s, 3H), 2.38 (s, 
3H), 2.31 (s, 3H).13C {1H} NMR (101 MHz, CDCl3) δ 146.5 (s), 143.3 (s), 138.7 (s), 136.5 (s), 
132.8 (s), 129.5 (s), 126.8 (s), 124.1 (s), 122.0 (s), 107.3 (s), 56.2 (s), 21.2 (s), 15.7 (s). HRMS 
(ESI-TOF) m/z: [M+H]+ calc’d for C15H17O2+: 229.1223. Found: 229.1219. 
Synthesis of 3,4'-dimethoxy-5-methyl-[1,1'-biphenyl]-4-ol (2.49c): 
To a solution of 2.40b (80 mg, 0.29 mmol, 1 eq) in CH2Cl2 10 mL, 0.03 M) 
methane sulfonic acid (76 µL, 1.18 mmol, 4 eq) was added. The reaction stirred 
at room temp for 30 minutes, at which point the reaction was quenched with pH 
5 phosphate buffer to a final pH of 3. The reaction mixture was then extracted 
with DCM (5 x 10 mL). The combined organics were dried over Na2SO4 and concentrated en 
vacuo to a yellow oil. The oil was purified by (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica 
gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were 
concentrated en vacuo to yield 2.49c as a white solid (25.1 mg, 36% yield). Mp = 122-124 °C. Rf 
= 0.44. IR (thin film, KBr): 3419 (br), 2948 (m), 2838 (m), 1608 (m), 1495 (m), 1466 (m), 1319 
(m), 1290 (m), 1240 (w), 1193 (w), 1179 (m), 1088 (m), 1070 (m), 1033 (w), 823 (w) cm-1. 1H 
NMR (400 MHz, CDCl3) δ 7.49 – 7.42 (m, 2H), 6.98 – 6.92 (m, 3H), 6.89 (d, J = 2.0 Hz, 1H), 
5.66 (s, 1H), 3.94 (s, 3H), 3.85 (s, 3H), 2.31 (s, 3H). 13C {1H} NMR (101 MHz, CDCl3) δ 158.8 
(s), 146.5 (s), 143.1 (s), 134.2 (s), 132.6 (s), 128.0 (s), 124.1 (s), 121.7 (s), 114.2 (s), 107.1 (s), 












Synthesis of 2-methoxy-6-methyl-4-(naphthalen-1-yl)phenol (2.49f): 
 
To a solution of 2.40e (35.3 mg, 0.11 mmol, 1 eq) in CH2Cl2 (3.6 mL, 0.03 M) 
methane sulfonic acid (28.8 µL, 0.44 mmol, 4 eq) was added. The reaction 
stirred at room temp for 1 hour, at which point the reaction was quenched with 
pH 5 phosphate buffer to a final pH of 3. The reaction mixture was then extracted 
with DCM (5 x 10 mL). The combined organics were dried over Na2SO4 and concentrated en vacuo 
to a yellow oil. The oil was purified by (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 
40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions were 
concentrated en vacuo to yield 2.49f as a clear oil (1.8 mg, 6% yield). Rf = 0.56 in 20% ethyl 
acetate. IR (thin film, KBr): 3676 (br), 2347 (m), 1653 (m), 1559 (m), 1507 (s), 1490 (m), 1399 
(m), 1315 (m), 1270 (w), 1233 (m), 1186 (m), 1117 (m), 1091 (m), 1008 (m), 785 (s), 712 (w), 
639 (m) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.4 Hz, 1H), 7.92 – 7.87 (m, 1H), 7.83 
(d, J = 8.2 Hz, 1H), 7.46 (dddd, J = 13.9, 8.3, 7.6, 4.1 Hz, 4H), 6.89 (d, J = 1.9 Hz, 1H), 6.86 (d, J 
= 1.8 Hz, 1H), 5.74 (s, 1H), 3.90 (s, 3H), 2.34 (s, 3H). 13C {1H} NMR (101 MHz, CDCl3) δ 146.1 
(s), 143.2 (s), 140.6 (s), 134.0 (s), 132.1 (s), 132.0 (s), 128.4 (s), 127.4 (s), 127.0 (s), 126.3 (s), 
126.0 (s), 125.8 (s), 125.5 (s), 124.9 (s), 123.7 (s), 110.4 (s), 56.3 (s), 15.7 (s). HRMS (ESI-TOF) 
m/z: [M+H]+ calc’d for C18H17O2+: 265.1223. Found: 265.1198. 
 
Synthesis of 2-methoxy-6-methyl-4-(thiophen-3-yl) phenol (2.49g): 
To a solution of 2.40f (22 mg, 0.09 mmol, 1 eq) in CH2Cl2 (3 mL, 0.03 M) 
methane sulfonic acid (30 µL, 0.35 mmol, 4 eq) was added. The reaction 
stirred at room temp for 30 minutes, at which point the reaction was quenched 
with pH 5 phosphate buffer to a final pH of 3. The reaction mixture was then 







en vacuo to a yellow oil. The oil was purified by (Biotage Isolera Prime, SiliCycle SiliaSep 25 g 
silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 mL). Product fractions 
were concentrated en vacuo to yield 2.49g as a yellow oil (4.2 mg, 21% yield). Rf = 0.53 in 20% 
ethyl acetate. IR (thin film, KBr): 3509 (br), 2937 (m), 1604 (m), 1536 (m), 1496 (w), 1463 (m), 
1410 (m), 1361 (m), 1344 (m), 1299 (w), 1247 (m), 1211 (m), 1170 (m), 1087 (m), 1067 (m), 947 
(w), 845 (w), 778 (m), 729 (m) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.33 (m, J = 5.1, 2.8 
Hz, 1H), 7.33 – 7.30 (m, 2H), 7.03 – 6.97 (m, J = 1.3, 0.5 Hz, 1H), 6.94 (m, 1H), 5.67 (s, 1H), 3.93 
(s, 3H), 2.30 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 146.5 (s), 143.3 (s), 142.8 (s), 127.7 (s), 
126.6 (s), 126.1 (s), 124.2 (s), 121.7 (s), 119.0 (s), 106.9 (s), 56.3 (s), 15.7 (s). HRMS (ESI-TOF) 
m/z: [M+H]+ calc’d for C12H13O2S+: 221.0631. Found: 221.0629. 
 
2.10.12. Synthesis of 3-hydroxy-4-methoxyphenyl ethanones 
1-(3-hydroxy-4-methoxyphenyl)ethan-1-one (2.45) and 1,1'-(3-hydroxy-4-methoxy-1,2-
phenylene)bis(ethan-1-one) (2.46): 
 
To a solution of 2.44 (23 mg, 0.11 mmol, 1 eq) in CH2Cl2 (3.6 mL, 0.03 M) at 0 °C, a 1M solution 
of boron trichloride in CH2Cl2 (10.4 µL, 0.16 mmol, 4 eq) was added. The reaction stirred at room 
temp for 15 minutes, at which point the reaction was quenched with pH 5 phosphate buffer to a 
final pH of 3. The reaction mixture was then extracted with DCM (5 x 10 mL). The combined 
organics were dried over Na2SO4 and concentrated en vacuo to a yellow oil. The oil was purified 
by (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-
25% EtOAc in hexanes (500 mL). Product fractions were concentrated en vacuo to yield 2.45 (4.7 





Characterization for 2.45 has been described previously.S10 
 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 2.1 Hz, 1H), 7.53 (s, 1H), 6.89 (d, J = 8.3 
Hz, 1H), 5.65 (s, 1H), 3.96 (s, 3H), 2.54 (s, 3H).  
 
	
Rf = 0.53 in 20% ethyl acetate. IR (thin film, KBr): 3355 (br), 2940 (m), 2360 (w), 
1701 (s), 1670 (m), 1576 (m), 1490 (w), 1458 (w), 1438 (w), 1359 (m), 1278 (s), 
1254 (m), 1137 (w), 1073 (w), 1046 (w), 970 (w), 847 (w), 808 (w) cm-1. 1H NMR 
(400 MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 6.50 (s, 1H), 
3.97 (s, 3H), 2.53 (s, 3H), 2.52 (s, 3H). 13C {1H} NMR (101 MHz, CDCl3) δ 203.9 (s), 197.6 (s), 
150.9 (s), 143.3 (s), 129.7 (s), 128.9 (s), 122.9 (s), 109.8 (s), 56.5 (s), 31.4 (s), 26.9 (s). HRMS 

























1H NMR of 2.31 
 









1H NMR of 2.33 
 

















1H NMR of 2.34 
  























1H NMR of 2.35
 
 











1H NMR of 2.36b 
 
 










1H NMR of 2.36c 
 











1H NMR of 2.36a 
 














a][1,2]diazepine-1,3,6(2H,9H)-trione (2.36d) in the presence of excess salt*:  
* Compound 2.36d is unstable and thus unable to be purified and isolated. The compound degraded 
via multiple chromatography techniques such as using silica, triethylamine capped silica, and 
neutral alumina column. Crystallization and tritration attempts were also unsuccessful. However, 
crude 1H NMR and 13C NMR of 2.36d containing known impurities allowed us to assign all 1H 
and 13C NMR peaks with exception of those in the aromatic region. In order to obtain this spectra 
with only known impurities, a solution of excess salt 2.2 (1.5 equiv) and 4-phenyl-1,2,4-triazoline-
3,5-dione (1 equiv) in CH2Cl2 was treated with triethylamine (1.2 equiv).  After an aqueous 
ammonium chloride wash, the reaction mixture contained only dimer 2.19, bicycle 2.36d, and 
PTAD (2.37b. Below is the 1H NMR of this reaction where peaks associated with 2.36d have been 
labeled accordingly. As PTAD only has aromatic 1H signals, the non-aromatic region possesses 
only signals from 2.36d and dimer 2.19,S3 making those from 2.36d easily identifiable. Below is 
the 13C NMR of this reaction where dimer peaks have been labeled as “d” and an “*” indicates the 















1H NMR spectra 2.40a 
 












1H NMR spectrum of 2.40b:	
 











1H NMR spectrum of 2.40c 
 










1H NMR spectrum of 2.40d 
 









1H NMR spectrum of 2.40e 
 










1H NMR spectrum of 2.40f 
 
 









1H NMR spectrum of 2.44 
 













1H NMR spectrum of 2.43a 
 








1H NMR spectrum of 2.43b 
	













1H NMR spectrum of 2.43c 
	
 






































1H NMR of 2.43f 
 
 






























1H NMR spectrum of 2.49a: 
 
 





































1H NMR spectrum of 2.49b: 
	
	













































1H NMR spectrum of 2.49f 
 
 









1H NMR spectrum of 2.49g 
 
 

















































1H NMR spectrum of 2.46 
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Studies on a Reductive Ring Opening Route to Atropisomeric Colchicine Analogs  
3.1. Introduction to Troponoid Atropisomerism 
Atropisomerism can be described as axial 
chirality in a molecule due to hindered rotation about 
a single bond, where sterics or other factors create 
high enough energy barriers to allow for individual 
isomers to be isolatable (Scheme 3.1).1 Molecules 
containing an atropisomeric axis can either racemize 
rapidly by having low energy barriers to rotation 
(class 1 atropisomers) or racemize much more slowly, 
taking over 6 months at physiological conditions to interconvert (class 3 atropisomers). Class 2 
atropisomers fall in between these, but are usually avoided in medicinal chemistry pursuits due to 
their unpredictability.2,3,4 Perhaps the most well-known atropisomeric compound is BINOL, which 
has a half-life to racemization of 2 million years and has proven to be an extremely valued chiral 
ligand.5 Scaffolds that can display atropisomeric character typically include biaryls, diaryl ethers, 
diaryl amines, benzamides, and anilides. Recently, our lab explored the particularly high rotational 
energy barriers of amide containing tropones in comparison to benzamides (Scheme 3.2A).6 The 
lower dihedral angle of 3.2 compared to its benzamide relative, 3.1, results in higher energy 
barriers to rotation between the aryl-amide axial bond. Our lab showed this both computationally, 
and experimentally. In addition, our lab was able to synthesize the amide tropones 
enantioselectively using chiral peptide catalysts developed by the Miller lab in the bromination of 
























Scheme 3.1: Examples of atropisomeric chirality.
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centers has been well-exploited in drug discovery, methods for the development of atropisomeric 
compounds are much less studied. However, the prevalence of molecules containing an 
atropisomeric axis in drug discovery has been increasing over the last decade. Approximately 30% 
of small molecule drugs that the FDA has approved since 2011 contain at least one freely 
interconverting axis of chirality, with an additional 16% have atropisomeric chiral characteristics.7 
In many cases the majority of activity belongs to one atropisomer, with the other atropisomer often 
being less potent or containing different properties.8,9 Some classic examples of FDA-approved 
atropiosmeric drugs include telenzepine, vancomycin, and colchicine. Telenzepine is widely 
discussed due to the fact that there is a drastic 500-fold difference in potency between its 
atropisomers.10 The natural product, ( -)-(aR,7S)-colchicine (3.5) is an FDA-approved therapeutic 
whereas its enantiomer is approximately 40-fold less potent. Fascinatingly, the acetamido group 
on colchicine stabilizes one diastereomer over the other, which is the reason that natural colchicine 
is indefinitely atropisomerically stable.11 These examples of activity differences between 
atropisomers of compounds, as well as some of the unique structural motifs that allow the stability 










ΔGcalc, rt = 24.2 kcal/mol
t1/2comp,rt = 10 hr
ΔGcalc, rt = 31.2 kcal/mol



































ΔG418 K = 30.1 kcal/mol
Scheme 3.2: Murelli group’s previous work in collaboration with the Miller group on the 




and recognize atropisomeric molecules would be widely appreciated from both a synthetic and 
medicinal chemistry standpoint. 
3.2. Introduction to Colchicine 
Colchicine, the primary alkaloid of the poisonous meadow saffron plant, presents an 
unusual 6-7-7 (C-B-A) ring structure (Figure 3.1A). It is not just widely known because of its 
atropisomeric character, but has been recognized for centuries for its medicinal properties. It has 
long been used to treat inflammatory-type diseases and is currently an FDA-approved drug for the 
treatment of gout and familial Mediterranean fever.12  
 
Colchicine has continued to remain prevalent in all areas of chemical research despite it 
being extensively studied for decades prior. In fact, a scifinder search shows that over three 
thousand publications involving topics related to colchicine have been published in just the past 5 
years alone. Importantly, colchicine and analogs are being studied for further potential indications 
including cardiovascular diseases.14 Colchicine’s biological activity is attributable to its ability to 
bind to tubulin (Figure 3.1B). Tubulin is a heavily studied protein because it is responsible for a 

















heterodimer consisting of alpha and beta subunits that polymerize into hollow microtubules,15 and 
inhibitors can function by either preventing its polymerization or depolymerization processes. 
Colchicine binds at the interface between the alpha and beta subunits of tubulin and upon this 
binding, there is a steric clash that prevents the protein from further polymerization.16 
 Tubulin inhibitors are of high interest to the medical community, and their benefits are 
best emphasized by the highly effective cancer drug, Taxol, which is a tubulin depolymerization 
inhibitor.17 Given this information, colchicine has long been examined as well for being a potent 
anti-cancer agent that inhibits cellular mitosis, however, it is highly cytotoxic and has a narrow 
therapeutic index.18 Regardless, there has been substantial research that has been aimed at 
developing colchicine binding site inhibitors (CBSI’s).19 The advantage of CBSIs for cancer 
treatment over other tubulin inhibitors stems from the fact that these compounds are potent 
vascular disrupting agents.20 Vascular disrupting agents specifically target tumor blood cells and 
have a relatively low toxicity profile. Another benefit is that most CBSI’s have a low molecular 
weight with easily chemically modifiable structures to improve the pharmacokinetic properties, 



















































Figure 3.2: Structure of potent tubulin binding agent combretastatin A-4 and other CBSI’s that are currently in phase
 II or III clinical trials.
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from high throughput screening. Figure 3.2 shows representative CBSI’s that have shown anti-
tumor activity. Combretastatin A-4 specifically has shown potent anti-cancer activity, and its 
analogs such as fosbretabulin and ombrabulin are currently in phase II and III clinical trials.21 
Other structures aside from combretastatin A-4 analogs have also been studied in clinical trials 
including tivantinib, plinabulin, and lisavanbulin.22 Interestingly, none of the molecules in Figure 
3.2 contain the 7-membered troponoid core of colchicine, and the known difficulty in the synthesis 
of troponoid structures makes this likely non-coincidental. The unique structure of colchicine 
however has not gone unnoticed to organic chemists, and has made it of synthetic interest for 
decades. 
Since the discovery of colchicine as a tubulin binding agent, its synthesis has been the 
target of over a dozen completed total syntheses dating back to the 1950’s.23 Each synthesis has 
employed a new strategy that improved upon the previous, exploiting new synthetic chemistry 
advancements. Although countless natural products have been viewed as important targets for 
synthesis, few have had such historical significance in progressing the field of synthetic organic 
chemistry more generally than colchicine has. 
Albert Eschenmoser was the first person 
to synthesize colchicine, taking 22 steps and 
obtained in 0.0006% overall yield.24 In the same 
year, van Tamelen synthesized colchicine in 19 
steps and 0.001% yield (Scheme 3.3).25 Unique 
to his synthesis was the use of an oxabridge 
intermediate, 3.6, which he advanced to the 7-
membered aromatic core of colchicine in 7 steps. It was not until nearly half a century later that 
Schmalz, 2005





















R = H, Van Tamelen, 1959
R = Me, Cha, 2000
0.001% overall yield, Van Tamelen
1.9% overall yield (90% ee), Cha




Scheme 3.3: Oxabridge intermediates in total syntheses efforts of 
colchicine.
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the use of the oxabridge intermediate was utilized again. In Cha’s enantioselective synthesis, he 
showed it only took 3 steps from 3.6 to access the troponoid core.26 However, the synthesis of this 
intermediate was low yielding and took 17 steps. Several years later in 2005, Schmalz and 
Graening utilized an oxabridged intermediate, 3.7, in their enantioselective synthesis that also 
allowed for fewer steps to the 7-membered ring core than previous syntheses.  
One of the most recent syntheses, accomplished by Li in 2017, was an impressive 9 steps 
with a 9.2% overall yield.27 Almost a year after his initial synthesis, he published another paper 
shortening the total synthesis to 8 steps (Scheme 3.4).28 Li also utilizes an oxabicyclic intermediate 
in his synthesis (3.11), which he accessed via an intramolecular oxidopyrylium cycloaddition from 
furan, 3.9. From there he used an approach similar to Cha’s for a 3-step route to the natural product. 
Importantly, Li’s synthesis does not generate the aromatic colchicine core until the final step, 
making the potential for analog synthesis not as accessible. Our lab gained inspiration from this 
synthesis in the use of the oxidopyrylium cycloaddition, a reaction extensively discussed in both 
Chapter 1 and Chapter 2. A simplified synthetic strategy, specifically one invoking an 
intermolecular construction of the A-C ring as well as an efficient route from the oxabicycle to the 
7-membered troponoid core, would be valuable to both medicinal chemistry and atropisomerism 


















































Scheme 3.4: Most recent total synthesis of colchicine (Li, 2018).
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3.3. Reductive Ring Opening Route to 2-Methoxytropones 
Throughout the history of colchicine total synthesis, the main synthetic challenge has 
proven to be the construction of the troponoid core as dicussed in section 3.2.23 This directly 
translates to difficulty in making colchicine-like analogs. Previously, our lab has thoroughly 
examined acid-mediated ring openings to troponoid systems, specifically, hydroxytropolones via 
a net isomerization process (Scheme 3.5A, 3.13 → 3.14). Since we have developed a highly 
efficient route to oxidopyrylium cycloadducts via intermolecular cycloaddition of 3-hydroxy-4-
pyrone derived dimers and a variety of alkynes as discussed in Chapter 2, our lab has been able to 
access over 200 hydroxy tropolones that have been recognized for their biological activity against 
dinuclear metalloenzymes.29 However, many troponoid natural products, including colchicine, 
contain only one neighboring oxygen containing group at the 2 position rather than two adjacent 
hydroxy groups that our lab has focused on. Examples of such natural products include  b-






















































Scheme 3.5A: Hypothesis for 2-tropone synthesis. B: 2-Tropone containing natural products.
C: Furan route to 2-tropones (Wright, 2012).
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stipitaldehyde (not shown). Thus, a synthetic method to rapidly access 2-substituted troponoids 
from the easily accessible 3-hydroxy-4-pyrone derived oxidopyrylium cycloadducts would not just 
be valuable in efforts towards colchicine analogs, but other troponoid natural products and their 
analogs as well. In Li’s synthesis (Scheme 3.4), looking at the conversion of 3.12 to 3.5 we 
imagined a scenario where a reductive ring opening from the oxabicycle could lead to a rapid route 
to the colchicine core (Scheme 3.5A, 3.15 → 3.16). Curious if this type of chemistry had been 
done before, we found a paper published in 2012 by the Wright group in which they subjected 
furan-derived bromine- containing oxabicycles (Scheme 3.5C, 3.17 → 3.18) to samarium iodide. 
This resulted in the elimination of the alkyl halide in order to access beta thujaplicin analogs (3.18 
→ 3.19).30 Interestingly, in their synthesis they reported compound 3.20, resulting from the 
elimination of the oxabridged functionality rather than the bromine. This was hopeful given the 
fact that cycloadducts made from our 3-hydroxy-4-pyrone derived intermolecular cycloaddition 
chemistry contain a methoxy group, and thus a worse leaving group than bromine. We 
hypothesized we may be able to get selective elimination of the oxabridge leading directly to the 
isocolchicine core in only 2 steps from our 3-hydroxy-4-pyrone starting materials. Initial attempts 
at this conversion were unsuccessful, leading to a mixture of un-isolatable aromatic products. 
Gratifyingly, we found that quenching the reaction with slightly acidic pH 2 phophate buffer 
successfully lead to the conversion of 3.21 → 3.24 (Scheme 3.6A) in 80% yield without further 
need of purification after workup. We then completed a substrate scope of both electron rich (3.25) 
and electron poor (3.26) aryl substituted methoxy tropones. The reaction also worked with maltol-
derived cycloadduct, 3.27, which unsurprisingly showed to be a lower yielding process. 
Fortunately, the chemistry also works with more sensitive ketone containing cycloadducts to yield 
3.28. In addition, the A-C core of colchicine (Scheme 3.6C, 3.36), also known as MTC, was able 
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to be synthesized using this chemistry from cycloaddition of 3.33 with alkyne 3.34 to yield the 
subsequent bicycle 3.35 followed by the reductive ring opening conditions.  
 
3.4. Synthesis of a Novel Colchicine Analog 
With the facile reductive ring opening method in hand, we then focused our attention on 
the synthesis of colchicine analogs. Researchers have done extensive SAR studies on colchicine 
giving insight into important functionalities for its activity and the precedence of these studies 
allows for insightful analog design. A summary of this information is presented in Scheme 3.7. It 
is known that the 3,4,5-trimethoxyphenyl ring (A ring) interacts with the colchicine binding site 





































3.29, 63% 3.32, 42%
80%
3.30, 52% 3.31, 20%
3.21, 39%a 3.22 3.23 3.24
Scheme 3.6A: Development of a samarium iodide mediated route to 2-methoxytropones. aSynthesized via 
heating with appropriate alkyne and dimer, 3.38 (see supplementary section for more details), 3.21 
synthesized in 39 % yield.B: Substrate scope examination. C: Synthesis of known MTC analog of colchicine
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troponoid ring (C ring) can provide inhibition of tubulin. The placement of the troponoid carbonyl 
and methoxy on the C ring are crucial, as swapping these positions as in isocolchicine shows loss 
of activity.31 The C ring, however, can be replaced with a 6-membered ring, as is shown in the 
potent tubulin binding agent, combretastatin A-4 (Section 3.2, Figure 3.2). The B ring however, 
is not believed to play an important role in the activity of colchicine except for the presence of the 
acetamido group in stabilizing the active atropisomer.  In fact, removal of the acetamido group 
(Scheme 3.7, 3.37) lowers the rotational energy barrier of colchicine to 22 kcal/mol.32 With the 
knowledge that the conformational stability of colchicine influences its activity, we imagined that 
removal of the B ring and placing bulky groups such as a methyl group as shown in 3.38, could 
lead to an increase in rotational energy barriers. Indeed, our lab conducted computational studies 
and found that the rotational energy barrier was exceedingly high, above 35 kcal/mol. Thus, we 
set out to synthesize 3.38 to examine both its atropisomeric characteristics and its potential 
biological activity. The process first involved the synthesis of alkyne, 3.41 (Scheme 3.8). Initially, 

















oxygens or removal 
decreases potency
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Incorporation of aliphatic and 
heterocyclic amines show
 potential for prodrug 
derivatization
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ΔG = 22 kcal/mol ΔG = > 35 kcal/mol
(computational)
3.37 3.38
Scheme 3.7: Hypothesis for the synthesis of an atropisomeric colchicine analog supported by 
computational data.
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due to the steric hindrance at that location. We then started from a brominated 3,4,5-
trimethoxytoluene (3.39), and attempted a Sonagashira coupling. This also initially proved 
unsuccessful given the fact that this is an extremely electron rich system, and the oxidative 
insertion of palladium favors electron deficient substrates. Synthesizing the iodo derivative (3.40) 
rather than from the bromo derivative and heating it overnight with sonagashira conditions, we 
successfully obtained the alkyne in a 96% yield over two steps (after desilylation). Cycloaddition 
with dimer 3.42 lead to the cycloadduct 3.43 that successfully formed the isocolchicine derivative, 
3.44, upon treatment with samarium iodide in 50% yield. Due to the tautomeric nature of tropolone 
3.45, it can be demethylated and then methylated to give a mixture of 3.44 and colchicine 
derivative, 3.38, in high yields. Use of a chiral IA column with hexanes and 2-propanol resulted 
in three peaks, two of which were the separated enantiomers of the colchicine-type derivative, and 
one of which being the mixture of the isocolchicine-type enantiomers. Gratifyingly, the 
isocolchine derivatives can be separated with different conditions by use of chiral IC column with 

































































Scheme 3.8: Synthetic route to desired colchicine analog. a. NIS (1 eq), TFA (30 mol %),CH3CN, rt, 8 hr.  b. Pd(PPh3)Cl2 ( 5 mol%), CuI (5 mol%),



















82 °C, 12 hr
3.45
3.39, R1 = H
 3.40, R1 = I, 86%
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configuration of the isolated compounds has not been concluded, but efforts are underway to obtain 
circular dichroism spectra of all 4 enantiomers (aR-3.38, aS-3.38, aR-3.44, aS-3.44). With the 
isolated enantiomers in hand, we then needed to confirm their stability and assess their potential 
biological activity in tubulin inhibition.  
3.5. Analysis of Atropisomeric Stability 
 As discussed previously, the calculated rotational energy barriers of 3.38 are above 35 
kcal/mol. With this in mind, obtaining experimental barriers may be difficult as the molecules 
would need to racemize at a temperature and time they could be successfully analyzed and without 
the concern for other potential decomposition. Previously, our lab had obtained experimental and 
computational rotational barriers for 3.2 (Section 3.1, Scheme 3.2) among other amide containing 
tropones.6 This was done by heating a 50% ee mixture at 145 °C for 90 minutes and analyzing its 
racemization via HPLC. The molecule racemized from 50 % ee to 10 % ee at this high temperature, 
and was determined to be a highly stable class 3 atropisomer with a calculated energy barrier of 
30.1 kcal/mol. Thus, before conducting a similar experiment, we first heated 3.38 at 145 °C for 60 
minutes, and analyzed its MPLC trace to see if any racemization could be observed. Figure 3.2A 
shows the separation of 3.38’s enantiomers on a chiral IA column in hexane and 2-propanol. Figure 
3.2B shows the MPLC result after heating the first peak enantiomer at 145 °C for 60 minutes and 
subjecting it to the same column conditions (10-100% Hex: IPA). The MPLC trace implies there 
is no apparent or at least substantial racemization that occurred. This result suggests that the 
rotational energy barriers are likely higher than the 30.1 kcal/mol obtained for 3.2, and help to 
support that the experimental rotational energy barrier is likely comparable to the calculated >35 
kcal/mol. The same exact studies were also done for the isocolchicine-type analog, 3.44, to which 
again no apparent racemization occurred (Figure 3.3A and B). In addition to this data, obtaining 
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HPLC traces of the enantiomers after heating is ideal as it can be quantitatively analyzed, and 
current studies are underway to obtain that information. However, regardless of the specific 
experimental value, it is apparent that these compounds are highly stable class 3 atropisomers and 







































Figure 3.4A: MPLC trace of 3.44 enantiomers. B: Heating peak 1 enantiomer at 145 °C to determine if racemization
occurs.
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3.6. Preliminary Biological Studies 
 Due to previous SAR studies done on colchicine binding site agents, we predicted that our 
analog would show biological activity as a potential tubulin binding agent. In order to test this, we 
collaborated with Dan Sackett at the NIH who was able to obtain growth inhibition (GI50) data on 
all four (aR-3.38, aS-3.38, aR-3.44, aS-3.44) isomers. The GI50 is the concentration for 50% 
maximal inhibition of cell proliferation. The cells used for these assays were PC-3 cells, a human 
prostate carcinoma cell line, and the compounds were tested in 10 different concentrations, 
produced by serial 3-fold dilutions. A stain was then added to measure redox activity in cells. The 
results of these studies are summarized in Figure 3.5. As predicted, one atropisomer of 3.38 was 
about ~10 fold more active than its corresponding enantiomer. Both of these were much more 
active than the isocolchicine-type analogs (3.44), which essentially showed no activity. This is 
consistent with the fact that isocolchicine is inactive, further supporting that the carbonyl-methoxy 
placement on the tropone ring is very important for activity. Due to the fact that we do not have 













(-)- colchicine(aR) GI50 PC-3  = 0.4 µM*


















GI50 PC-3 = 5 nM
GI50 PC-3  = 0.4-1.3 µM GI50 PC-3  = 8 nM GI50 






C GI50 PC-3  = 10.7 - 14.9 µM*
D GI50 PC-3  = 10.8 -96.0 µM*
O
MeO
Figure 3.5: Cell assay data on 3.38, 3.44, and control compounds. Note*: Stereochemistry
is not confirmed, this is hypothesized based on activity.
3.443.38
	 127	
isomer of 3.38 is the aR isomer. We are making this assumption since it is known that the aR 
conformation of natural colchicine is the active conformer.1 This will however need to be 
confirmed through obtaining CD spectra of the compounds. Shown in Figure 3.5 are also known 
potent tubulin inhibitors, colchicine, 2-methoxy-5-(2,3,4-trimethoxyphenyl)-2,4,6-
cycloheptatrien-1-one (MTC), and combretastatin-A4, which were tested in the same assay as 
controls to the synthesized analogs. The analogs are significantly less potent than these agents, 
while still being considered active. Importantly, unlike colchicine, MTC is non-atropisomeric, 
although still highly active. 3.38 as shown in Section 3.6 is highly atropisomeric, and less active 
than MTC. We hypothesize that this is because MTC can rotate to the necessary conformation 
needed to bind quickly and irreversibly to tubulin, while 3.38 is locked into position and unable to 
achieve the seemingly necessary dihedral angle. Colchicine, on the other hand, is atropisomeric 
with the necessary dihedral angle to bind slowly and irreversibly bind to tubulin.33 This data 
suggests that there are many more studies to be done regarding the use of this synthetic method to 
access A-C ring analogs with alternative dihedral angles in order to understand both the kinetics 
of binding to the CBS in tubulin and its relation to biological activity. To the best of our knowledge, 
in addition to MTC, there are currently only 3 known A-C ring colchicine analogs known other 
than MTC that have been studied. Figure 3.6 displays these, one of which was semi-synthetically 
synthesized by Berg from colchicine in 1997 (3.46) and showed no tubulin inhibition.34 However, 
























contain atropisomeric stability. The chloro derivative, 3.48, was synthesized by Banwell in 1988 
and showed to be biologically active.5 In this same work he also synthesized an alternative chloro 
derivative (not shown) that did not show biological activity. 
Thus, due to the synthetic difficulty of making these A-C analogs, almost all colchicine 
analogs examined for biological activity have contained a B ring variant and all were made via a 
semisynthetic approach.36 Therefore, this work represents a valued de-novo method to potentially 
access a variety of unique A-C analogs from readily accessible alkynes and pyrone starting 
materials. Given the extensive prevalence of colchicine, CBSI’s, and tubulin in the literature and 
in drug design, the discovery of a new class of active atropisomeric A-C analogs is significant 
from a synthetic, biological, and physical organic perspective.  
 
3.7. Future Studies and Conclusions 
 Over the past few decades, researchers have moved away from tropone and colchicine-like 
structures to study tubulin inhibition. As stated previously, this is likely due to the fact that there 
are more easily synthesizable compounds that show promising activity. However, the A-C ring 
analogs presented in this work are extremely unique structures as highlighted in the last section. 
The reductive ring opening of easily accessible oxidopyrylium cycloadducts opens up doors for a 
new rapid approach to synthetic A-C analogs. Like colchicine, the small molecular weight and 
easily chemically modifiable structures of these can allow for further medicinal chemistry pursuits 
of their relatives. In addition, the binding of these compounds could provide insight into the unique 
kinetics observed between various CBSI’s. For example, its unique that colchicine binds slowly 
and irreversibly, while MTC binds quickly and reversibly. It could be interesting to understand 
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how alternative analogs bind and gain understanding on how the tropone dihedral angle effects 
this.  
Our lab intends on doing further biological studies by sending out the compounds to the 
NCIS 60 human tumor cell lines screen which looks at 60 different cell lines to identify compounds 
with grown inhibition or killing of tumor cell lines.  
A short-term goal of the lab also involves a total synthesis of colchicine that exploits the 
efficiency of the samarium iodide ring opening. The reductive ring opening and 
demethylation/methylation steps were already worked out on the colchicine analogs. Thus, if a 
route to the kojic acid derived tether could be formed, then only 5 steps or less may be needed to 
access the natural product. Aforementioned, given the prevalence of 2-substituted tropones, this 
route could also provide a route to alternative tropone natural products and the evaluation of those 
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3.9. Supplementary Experimental Details 
Dan Sackett at the NIH performed all cell assay data for the analogs to obtain GI50 data. 
Diana Kapyakeva in collaboration with Dr. Emilio Gallichio obtained the computational data in 
this chapter. Anastasiya Lyubimova performed some of the synthetic experiments and obtained 
characterization data for some compounds in this work. 
3.9.1. General Information   
All starting materials and reagents were purchased from commercially available sources 
and used without further purification. 1H NMR shifts are measured using the solvent residual peak 
as the internal standard (CDCl3 δ 7.26, CD3CN δ 1.93), and reported as follows: chemical shift, 
multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd =doublet of doublet, q = 
quartet, m = multiplet), coupling constant (Hz), and integration. 13C NMR shifts are measured 
using the solvent residual peak as the internal standard (CDCl3 δ 77.2, CD3CN δ 1.3 and δ 117.7), 
and reported as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong 
(s), medium (m), and weak (w). Microwave reactions were performed via the Biotage Initiator 2.5. 
Purification via normal phase column chromatography was performed on the Biotage Isolera 
Prime, with SiliCycle SiliaSep 12 g, 25 g, or 40 g cartridges, in solvent systems of ethyl acetate 
(EtOAc) in hexane, or dichloromethane (DCM) and acetonitrile (CH3CN). Column gradients are 
measured in terms of column volumes (CV). Mass spectra were recorded on a spectrometer by the 
electrospray ionization (ESI) technique with a time-of-flight (TOF) mass analyzer. Chiral 
separation was achieved with columns (chiral supports) from Daicel Chemical Industries 
(Chiralpak IA and Chiralpak IC) at ambient temperature. Computational data was obtained using 




3.9.2. Synthesis of Oxidopyrylium [5 + 2] Cycloadducts. 
Cycloadducts 3.21, 3.26, 3.27, and 3.28 were synthesized per previously reported 
procedures.S1,S2,S3  Oxidopyrylium dimer cycloaddition starting material, 3.42, was synthesized 
previously by our lab.S1 Oxidopyrylium dimer 3.33 synthesis and characterization is shown below. 
 
Synthesis of oxidopyrylium dimer starting material (1R,2R,6R,7R)-6,9-dimethoxy-3,11-
dioxatricyclo[5.3.1.12,6]dodeca-4,9-diene-8,12-dione (3.33): 
 
In a round bottom flask, triflate salt synthesized and characterized previouslyS4 (10 
g, 36 mmol, 1 eq) was dissolved in CH2Cl2 (75 mL, 0.5 M). As triethyl amine (10 
mL, 72 mmol, 2 eq) was added to the mixture in the flask, the solid dissolved. It 
was left at room temperature for 15 minutes. After reaction time, aqueous ammonium chloride (75 
mL) was added.  The organic layer was isolated and the aqueous layer was extracted with CH2Cl2, 
(2 x 75 mL).  Combined organics were dried over Na2SO4, filtered, and concentrated under reduced 
pressure to yield a pale orange solid in 3g (15.8 mmol, 66% yield). Rf = 0.8 in 20% ethyl 
acetate/hexanes. Mp: 124-128 °C. IR (ATR, ZnSe) 3385 (w), 3072 (w), 2983 (br), 2840 (br), 
1748 (s), 1702 (s), 1614 (s), 1453 (w), 1364 (m), 1261 (m), 1206 (m),1158 (s), 1139 (s), 917 (m), 
875 (m), 820 (m). 1H NMR (400 MHz, CDCl3) δ 6.71 (d, J = 5.9 Hz, 1H), 6.00 (m, 1H), 4.99 (d, 
J = 5.9 Hz, 1H), 4.89 – 4.80 (m, 1H), 4.61 – 4.54 (m, 1H), 4.48 (m, 1H), 3.62 (s, 3H), 3.46 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 197.3 (s), 185.1 (s), 150.8 (s), 149.3 (s), 112.9 (s), 100.5 (s), 86.9 








Synthesis of 1-ethynyl-2,3,4-trimethoxybenzene (3.34): 
 
To a flame dried µwave vial (10-20 mL) equipped with stir bar was added 1-
bromo-2,3,4-trimethoxybenzene (2 g, 8.1 mmol, 1 eq) followed by 
bis(triphenylphosphine)palladium chloride (285 mg, 0.41 mmol, 0.05 eq) and 
copper iodide (77 mg, 0.41 mmol, 0.05 eq). The reaction vessel was sealed and purged with argon. 
Toluene (5 mL) and Triethylamine (10 mL) were then added to the reaction and argon was bubbled 
through the resulting solution for approximately 10 minutes. Trimethylsilyl acetylene was added 
via syringe (1.74 mL, 12.2 mmol, 1.5 eq) and then heated at 90 °C for 40 hours. The solution was 
then cooled to room temperature, filtered through celite, and concentrated under reduced pressure. 
The resulting 2 grams of orange oil was then dissolved in 15 mL of methanol and 5 grams of 
potassium carbonate was added. The mixture was stirred at room temp for approximately 24 hours, 
diluted with DCM and then washed with water (2 x 15 mL). The organic layer was dried over 
Na2SO4, filtered, and then concentrated under reduced pressure. The resulting oil was purified by 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 25 g silica gel, 40-63 µm 60 Å, solvent 
gradient: 0-25% EtOAc in hexanes (500 mL)). Product fractions were concentrated en vacuo to 
yield 3.34 as a clear oil (350 mg, 23% yield over two steps). Characterization has been reported 
previously.S5 1H NMR (400 MHz, CDCl3) δ 7.00 (d, J = 8.6 Hz, 1H), 6.46 (d, J = 8.6 Hz, 1H), 










To a solution of 3.33 (35 mg, 0.14 mmol, 1 eq) in CDCl3 (500 uL, 0.2 M) in a 
µwave vial (0.5 - 2 mL) was added 3.34 (350 mg, 1.8 mmol, 13 eq). The 
reaction was subjected to microwave irradiation at 150 °C for 10 hours. The 
resulting solution was immediately subjected to purification via column 
chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 10 g silica gel, 40-
63 µm 60 Å, solvent gradient: 0-100% EtOAc in hexanes (500 mL)). Product fractions were 
concentrated en vacuo to yield 3.35 as a pale, yellow oil (8.6 mg, 10% yield). Rf = 0.8 in 60 % 
ethyl acetate/pentane. IR (thin film, KBr): 2938 (w), 1708 (s), 1611 (w), 1493 (m), 1464 (w), 
1415 (w), 1343 (w), 1291 (m), 1241 (w), 1135 (w), 1084 (s), 1005 (w), 914 (s), 815 (w), 742 (m) 
cm-1. 1H NMR (400 MHz, CDCl3): δ 6.94 (d, J = 8.8 Hz, 1H), 6.68 (d, J = 8.8 Hz, 1H), 6.63 (d, 
J = 2.6 Hz, 1H), 6.28 (d, J = 4.8 Hz, 1H), 5.60 (d, J = 4.8 Hz, 1H), 5.09 (d, J = 2.6 Hz, 1H), 3.90 
(s, 2H), 3.89 (s, 2H), 3.88 (s, 2H), 3.56 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 190.0 (s), 154.8 
(s), 152.4 (s), 152.2 (s), 147.1 (s), 142.9 (s), 122.7 (s), 120.5 (s), 119.2 (s), 115.7 (s), 107.5 (s), 
87.9 (s), 80.2 (s), 61.0 (s), 60.7 (s), 56.2 (s), 54.8 (s). HRMS (ESI+ TOF) m/z: (M+H)+ Calc’d for 














dien-2-one (3.25):  
To a solution of 3.42 (150 mg, 0.53 mmol, 1 eq) in CDCl3 (1 mL, 0.5 M) was 
added 4-ethynylanisole (354 µL, 2.7 mmol, 5 eq) in a sealed µwave vial (0.5-
2 mL). The reaction was subjected to µwave at 120 °C for 2 h, and immediately 
purified by chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 10 g 
silica gel, 40-63 µm 60 Å, solvent gradient: 0-25% EtOAc in hexanes (500 
mL)). Product fractions were concentrated en vacuo to yield 3.42 as a yellow oil (137 mg, 48% 
yield). Rf = 0.12 in 60 % ethyl acetate/pentane. IR (thin film, KBr): 2936 (w), 2838 (w), 1844 
(m), 1710 (s), 1607 (s), 1510 (s), 1459 (w), 1380 (w), 1254 (s), 1177 (w), 1132 (m), 10 59 (w), 
1032 (w), 989 (w), 863 (w), 830 (w), 797 (w) cm -1. 1H NMR (400 MHz, CDCl3): 1H NMR (400 
MHz, CDCl3) δ 7.23 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 6.16-6.17 (m 2H), 4.96 (m, 1H), 
3.83 (s, 3H), 3.59 (s, 3H), 1.68 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 190.1 (s), 160.1 (s), 158.4 
(s), 146.2 (s), 127.5 (s), 125.6 (s), 121.0 (s), 119.2 (s), 114.3 (s), 86.4 (s), 85.8 (s), 55.5 (s), 54.8 
(s), 22.4 (s). HRMS (ESI+ TOF) m/z: (M+H)+ Calc’d for C16H17O4+: 273.1121. Found: 273.1122.  
 
3.9.3. Synthesis of 2-methoxytropones via reductive ring-opening. 
General procedure: To a flame dried round bottom flask equipped with stir bar is added 
cycloadduct (3.21, 3.25-3.28 1 eq) dissolved in THF (0.2 M). The reaction vessel is subsequently 
purged with argon. Under argon, a 0.1 M solution of samarium iodide in THF is added via syringe 
(5 eq). The solution is allowed to stir for a couple minutes before being quenched with pH 2 
phosphate buffer. The cloudy mixture is then allowed to stir for 3-6 hours at room temperature. 







water and extracted with Et2O (3 x 15 mL). The combined organics are then washed with an 
aqueous Rochelle’s salt solution (3 x 15 mL), followed by water, (1 x 15 mL) and brine (1 x 15 
mL). The combined organics are then dried with Na2SO4, filtered, and concentrated en vacuo. The 
resulting oil is purified via chromatography (Biotage Isolera Prime, SiliCycle SiliaSep 10 g silica 
gel, 40-63 µm 60 Å, solvent gradient: 0-100% EtOAc in hexanes (500 mL)). Product fractions 




3.24 obtained from 3.21 (10 mg, 0.04 mmol) as a pale-yellow oil (7.5 mg, 80%). 
Rf = 0.10 in 60 % ethyl acetate/pentane. IR (thin film, KBr): 2882 (w), 2843 
(w), 2363 (w), 1621 (m), 1571 (s), 1473 (w) , 1456 (w), 1440 (w), 1303 (m), 
1268 (m), 1190 (w), 1159 (s), 974 (w), 879 (w), 852 (w), 777 (w), 709 (w) cm-1. 1H NMR (400 
MHz, CDCl3) δ 7.46 – 7.40 (m, 2H), 7.39 – 7.33 (m, J = 5.1, 3.7 Hz, 1H), 7.24 – 7.19 (m, 3H), 
7.11 – 7.06 (m, J = 12.8 Hz, 1H), 6.77 (s, 1H), 3.97 (s, 3H), 2.25 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 179.3 (s), 162.8 (s), 143.4 (s), 140.9 (s), 140.7 (s), 133.7 (s), 128.8 (s), 128.6 (s), 127.6 
(s), 118.0 (s), 56.3 (s), 26.9 (s). HRMS (ESI+ TOF) m/z: (M+H)+ Calc’d for C15H15O2+: 227.1067. 














3.29 obtained from 3.25 (20 mg, 0.07 mmol) as a yellow oil (12 mg, 63%). Rf 
= 0.12 in 60 % ethyl acetate/pentane. IR (thin film, KBr): 2935 (br), 2837 
(w), 2359 (w), 1607 (s), 1575 (s), 1512 (s), 1457 (m), 1288 (m), 1252 (s), 1178 
(m), 1158 (m), 1033 (m), 976 (w), 834 (m) cm-1.1H NMR (400 MHz, CDCl3) 
δ 7.24 (d, J = 12.8 Hz, 1H), 7.17 (d, 2H), 7.10 (d, J = 12.8 Hz, 1H), 6.97 (d, J 
= 8.8 Hz, 2H), 6.79 (s, 1H), 3.99 (s, 3H), 3.88 (s, 3H), 2.29 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 179.3 (s), 162.6 (s), 159.0 (s), 141.1 (s), 140.8 (s), 140.7 (s), 135.8 (s), 133.6 (s), 129.9 (s), 118.1 
(s), 114.1 (s), 56.2 (s), 55.5 (s), 27.0 (s). HRMS (ESI+ TOF) m/z: (M+H)+ Calc’d for C16H17O3+: 




3.30 obtained from 3.26 (45 mg, 0.15mmol) as a clear oil (22 mg, 52%). Rf = 
0.11 in 60 % ethyl acetate/ pentane. IR (thin film, KBr): 2930 (w), 2838 (w), 
1629 (m), 1571 (s), 1464 (w), 1325 (s), 1271 (m), 1160 (m), 1107 (m), 1067 
(m), 1017 (w), 977 (w), 879 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, 
J = 8.0 Hz, 10H), 7.36 (d, J = 7.9 Hz, 10H), 7.14 (d, J = 12.7 Hz, 2H), 7.08 (d, 
J = 12.8 Hz, 1H), 6.75 (s, 5H), 3.98 (s, 3H), 2.23 (s, 14H). 13C NMR (101 MHz, CDCl3) δ 179.2 










125.8 (q, 3.7 Hz), 124.2 (q, J = 345.5 Hz), 117.6 (s), 56.34 (s), 26.9 (s). HRMS (ESI+ TOF) m/z: 




3.31 obtained from 3.27 (25 mg, 0.10 mmol) as a clear oil (4.5 mg, 20%). Rf = 
0.18 in 60 % ethyl acetate/pentane. IR (thin film, KBr): 3357 (br), 2917 (br), 
1717 (w), 1531 (m), 1558 (m), 1491 (w), 1461 (w), 1366 (m), 1285 (w), 1247 
(s), 1181 (m), 1081 (m), 1049 (m), 981 (w), 700 (m) cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.75 (s, 1H), 7.53 – 7.35 (m, 6H), 7.19 (dd, J = 10.2, 1.5 Hz, 1H), 6.85 (d, J = 10.2 Hz, 
1H), 3.97 (s, 3H), 2.46 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 179.4 (s), 162.3 (s), 146.5 (s), 
143.3 (s), 140.9 (s), 137.7 (s), 129.7 (s), 129.0 (s), 128.0 (s), 127.7 (s), 112.7 (s), 56.4 (s), 24.5 (s). 




3.32 obtained from 3.28 (12.1 mg, 0.06 mmol) as a clear oil (4.8 mg, 42%).	Rf 
= 0.10 in 60 % ethyl acetate/ pentane. IR (thin film, KBr): 2929 (br), 1696 (m), 
1619 (s), 1578 (s), 1481 (m), 1357 (m), 1311 (w), 1270 (m), 1229 (s), 1161 (s), 
976 (w), 873 (w), 850 (w), 516 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.17 
(d, J = 12.7 Hz, 1H), 7.10 (d, J = 12.7 Hz, 1H), 6.62 (s, 1H), 3.97 (s, 3H), 2.51 (s, 3H), 2.43 (s, 










134.2 (s), 117.6 (s), 56.5 (s), 30.7 (s), 25.7 (s). HRMS (ESI+ TOF) m/z: (M+H)+ Calc’d for 
C11H13O3+: 193.0859. Found: 193.0862. 
 
2-methoxy-5-(2,3,4-trimethoxyphenyl)cyclohepta-2,4,6-trien-1-one (3.36, MTC): 
 
3.36 obtained from 3.35 (15 mg, 0.05 mmol) as a clear oil (6 mg, 41%). 3.36 
has been characterized previously.S6 1H NMR (400 MHz, CDCl3) δ 7.45 (m, 
1H), 7.26 (m, 1H), 7.16 (m, 1H), 6.96 (m, 1H), 6.80 (m, 1H), 6.73 (m, 1H), 
4.00 (s, 3H), 3.92 (s, 3H), 3.90 (s, 3H), 3.72 (s, 3H). 
 
 
3.9.4. Intermediates in the synthesis of colchicine analog target.  
Synthesis of 2-iodo-3,4,5-trimethoxy-1-methylbenzene (3.40): 
 
To a solution of 3,4,5-trimethoxytoluene (3 g, 16.4 mmol, 1 eq) in CH3CN (0.8 
M) is added N-iodosuccinimide (3.7 g, 16.4 mmol, 1 eq) and trifluoroacetic 
acid (376 µL, 4.9 mmol, 0.3 eq) in a round bottom flask. The solution is stirred 
at room temperature for 8 hours. Upon completion, the reaction is diluted in DCM and washed 
with sodium thiosulfate (3 x 20 mL), water (2 x 20 mL), and brine (2 x 20 mL). The organic layer 
is then dried with Na2SO4, filtered, and concentrated en vacuo to yield 3.40 as an orange oil (4.3 
g, 86% yield). This compound has been characterized previously.S7 1H NMR (400 MHz, CDCl3) 












Synthesis of 2-ethynyl-3,4,5-trimethoxy-1-methylbenzene (3.41): 
 
To a flame dried 100 mL round bottom flask equipped with stir bar was 
added 3.40 (5g, 16.2 mmol, 1 eq) followed by 
bis(triphenylphosphine)palladium chloride (570 mg, 0.8 mmol, 0.05 eq) 
and copper iodide (155 mg, 0.81 mmol, 0.05 eq). The reaction vessel was sealed and purged with 
argon. Toluene (15 mL, 1 M) and triethylamine (20 mL, 0.8 M) were then added to the reaction 
and argon was bubbled through the resulting solution for approximately 10 minutes. Trimethylsilyl 
acetylene was added under argon via syringe (3.47 mL, 24.3 mmol, 1.5 eq) and then heated at 90 
°C for 16 hours. The solution was then cooled to room temperature, filtered through celite, and 
concentrated under reduced pressure. The resulting 6.37 grams of orange oil was then dissolved in 
20 mL of methanol and 15 grams of potassium carbonate was added. The mixture was stirred at 
room temp for approximately 24 hours, diluted with DCM and then washed with water (2 x 30 
mL). The organic layer was dried over Na2SO4, filtered, and then concentrated under reduced 
pressure. The resulting oil was purified by chromatography (Biotage Isolera Prime, SiliCycle 
SiliaSep 40 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-100% EtOAc in hexanes (500 mL)). 
Product fractions were concentrated en vacuo to yield 3.41 as a pale, yellow solid (3.2 g, 96% 
yield). Rf = 0.94 in 60 % ethyl acetate/pentane. Mp: 52-53 °C. IR (thin film, KBr): 3273 (br), 
2937 (m), 1596 (m), 1493 (m), 1463 (w), 1400 (w), 1335 (s), 1246 (m), 1124 (s), 1077 (w), 1034 
(w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.50 (s, 1H), 3.94 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.40 
(s, 1H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 155.3 (s), 153.8 (s), 139.8 (s), 137.5 (s), 
109.1 (s), 108.6 (s), 83.7 (s), 78.6 (s), 61.1 (s), 61.0 (s), 55.9 (s), 20.7 (s). HRMS (ESI+ TOF) 









In a µwave vial (2-5 mL), to solution of 3.42 (362 mg, 1.28 mmol, 1 eq) in 
CDCl3 (0.4 M) is added alkyne 3.41 (3.2 g, 15.4 mmol, 12 eq). The mixture 
was subjected to microwave irradiation at 120 °C for 2 hours. Upon 
completion, the reaction is immediately purified via chromotagraphy (Biotage 
Isolera Prime, SiliCycle SiliaSep 40 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-100% EtOAc 
in hexanes (500 mL)). Product fractions were concentrated en vacuo to yield 3.43 as a yellow oil 
(456 mg, 52% yield). Rf = 0.87 in 60 % ethyl acetate/pentane. IR (thin film, KBr): 2937 (br), 
1709 (s), 1608 (m), 1493 (m), 1463 (m), 1397 (m), 1333 (m), 1195 (w), 1175 (w), 1137 (s), 1106 
(s), 1037 (w), 993 (m), 914 (w), 864 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.58 (s, 1H), 6.26 
(s, 1H), 6.20 (m, 1H), 4.98 (m, 1H), 3.85 (s, 3H), 3.85 (s, 3H), 3.63 (s, 3H), 3.60 (s, 3H), 2.20 (s, 
3H), 1.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 191.0 (s), 155.3 (s), 153.2 (s), 151.2 (s), 144.3 
(s), 140.2 (s), 132.6 (s), 127.3 (s), 124.0 (s), 120.1 (s), 110.0 (s), 88.0 (s), 86.5 (s), 61.3 (s), 60.8 
(s), 56.1 (s), 54.7 (s), 21.3 (s), 21.0 (s). HRMS (ESI+ TOF) m/z: (M+H)+ Calc’d for C19H23O6+: 

















To 3 separate flame dried µwave vials (10-20 mL) equipped with stir bars, is 
added cycloadduct 3.43 (147 mg, 0.42 mmol, 1 eq) in 2 mL of THF (0.2 M) to 
each vial. The reaction vessels are purged with argon, and a 0.1 M solution of 
samarium iodide in THF is added via syringe (25.4 mL each, 6 eq). The 
resulting solutions are allowed to stir at room temperature for a couple minutes before being 
quenched with 30 mL pH 3 phosphate buffer. The cloudy mixture is then stirred at room 
temperature for 3 hours at which then all three reaction mixtures are combined and the THF is 
removed en vacuo. The resulting solution is then diluted with DI water, and extracted with Et2O 
(5 x 30 mL). The combined organics are then washed with Rochelle’s salt (3 x 30 mL), water (1 x 
30 mL), and brine (1 x 30 mL). The organic layer is then dried with Na2SO4, filtered, and 
concentrated en vacuo. The dark red oil is then purified via chromotagraphy (Biotage Isolera 
Prime, SiliCycle SiliaSep 40 g silica gel, 40-63 µm 60 Å, solvent gradient: 0-100% acetonitrile in 
dichloromethane (500 mL)). Product fractions were concentrated en vacuo to yield 3.44 as a pale, 
yellow oil (209 mg, 50% yield). A chiral Diacel IC column in DCM/Acetonitrile (0-100%) was 
used to separate the enantiomers. Rf = 0.10 in 60 % ethyl acetate: pentane. IR (thin film, KBr): 
2937 (br), 1621 (w), 1575 (s), 1460 (m), 1398 (m), 1333 (s), 1266 (m), 1194 (w), 1158 (s), 1138 
(s), 1099 (s), 1049 (w), 1001 (w), 921 (w), 834 (w), 729 (w). 1H NMR (400 MHz, CDCl3) δ 7.11 
(d, J = 12.7 Hz, 1H), 7.05 (d, J = 12.7 Hz, 1H), 6.79 (s, 1H), 6.58 (s, 1H), 3.97 (s, 3H), 3.89 (s, 
3H), 3.87 (s, 3H), 3.68 (s, 3H), 2.13 (s, 3H), 1.99 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 179.5 








129.1 (s), 117.7 (s), 109.2 (s), 61.1 (s), 61.0 (s), 56.1 (s), 56.1 (s), 26.0 (s), 19.9 (s). HRMS (ESI+ 





To a µwave vial (10-20 mL) equipped with stir bar was added 3.44 (209 mg, 
0.63 mmol, 1 eq) dissolved in Ac2OH (3 mL, 0.2 M) and 8 mL of a 12N HCl 
solution was added. The solution was subjected to µwave irradiation at 100 °C 
for 10 hours. Upon completion, the reaction was quenched with 5 mL sodium 
carbonate and extracted with DCM (5 x 10 mL). The organics were combined, dried with Na2SO4, 
filtered, and concentrated en vacuo. The resulting oil was dissolved in 10 mL of toluene and 
concentrated en vacuo again. This process was repeated 5 times to remove residual acetic acid and 
yield pure 3.45 as a dark brown oil (178 mg, 90% yield). Rf = 0.25 in 60 % ethyl acetate: pentane. 
IR (thin film, KBr): 2926 (br), 2849 (w), 1591 (s), 1518 (w), 1492 (w), 1438 (s), 1399 (w), 1365 
(m), 1333 (m), 1302 (m), 1270 (w), 1235 (w), 1141 (w), 1103 (w), 1083 (w) cm-1. 1H NMR (400 
MHz, CDCl3) δ 7.44 (s, 1H), 7.22 (d, J = 11.6 Hz, 1H), 7.18 (d, J = 11.6 Hz, 1H), 6.58 (s, 1H), 
3.88 (s, 3H), 3.86 (s, 3H), 3.66 (s, 3H), 2.12 (s, 3H), 1.97 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
171.6 (s), 168.5 (s), 153.1 (s), 150.4 (s), 149.0 (s), 140.4 (s), 140.4 (s), 138.6 (s), 130.7 (s), 129.4 
(s), 125.7 (s), 123.2 (s), 109.2 (s), 61.1 (s), 60.9 (s), 56.1 (s), 26.4 (s), 20.0 (s). HRMS (ESI+ TOF) 












To a flame dried µwave vial (2-5 mL) equipped with stir bar is added 3.45 
(170 mg, 0.54 mmol, 1 eq) in CH3CN (3mL, 0.2 M), K2CO3 (223 mg, 1.62 
mmol, 3 eq), and dicylohexyl-18-crown-6 (20 mg, 0.054 mmol, 0.10 eq). 
The reaction vessel is sealed and purged with argon. Under argon, MeI is 
added via syringe (166 µL, 2.7 mmol, 5 eq). The reaction mixture is heated at 82 °C for 9 hours in 
an oil bath. Upon completion, the reaction mixture is diluted with DCM, washed with sodium 
hydroxide (2 x 10 mL), sodium carbonate (1 x 10 mL), water (1 x 10 mL), and brine (1 x 10 mL). 
The combined organics are dried with Na2SO4, filtered, and concentrated en vacuo. The resulting 
oil is then purified by chromotagraphy (Biotage Isolera Prime, SiliCycle SiliaSep 10 g silica gel, 
40-63 µm 60 Å, solvent gradient: 0-100% acetonitrile in dichloromethane (500 mL)). Product 
fractions were concentrated en vacuo to yield a mixture of 3.38 and 3.44 as a pale, yellow oil (131 
mg, 74% yield). A chiral Diacel IA column in Hex/2-propanol (10-100%) was used to separate the 
enantiomers. Rf = 0.10 in 60 % ethyl acetate: pentane. IR (thin film, KBr): 2936 (w), 2840 (w), 
1752 (w), 1620 (m), 1589 (s), 1492 (m), 1462 (m), 1400 (m), 1335 (m), 1265 (m), 1248 (s), 1195 
(w), 1139 (m), 1106 (m), 1088 (m), 1028 (w), 1000 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.40 
(s, 1H), 6.85 (d, J = 10.5 Hz, 1H), 6.68 (d, J = 10.5 Hz, 1H), 6.60 (s, 1H), 3.98 (s, 3H), 3.91 (s, 
3H), 3.89 (s, 3H), 3.73 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 179.4 
(s), 163.8 (s), 153.0 (s), 150.6 (s), 148.7 (s), 140.3 (s), 139.9 (s), 138.1 (s), 132.7 (s), 130.9 (s), 
129.2 (s), 111.4 (s), 109.1 (s), 61.1 (s), 60.9 (s), 56.2 (s), 56.1 (s), 26.5 (s), 20.0 (s). HRMS (ESI+ 










3.9.5. NMR Spectra 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.9.6. Supplementary References 
S1-	Meck, C.; Mohd, N.; Murelli, R.P. Org. Lett. 2012, 14, 5988-5991. 
 
S2-	Hirsch, D. R.; Cox, G. C.; D'Erasmo, M. P.; Shakya, T.; Meck, C.; Mohd, N.; Wright, G. D.; 
Murelli R. P. Bioorg. Med. Chem. Lett. 2014, 24, 4943-4947. 
 
S3-	Bejcek, L. P.; Garimallaprabhakaran, A. K.; Suyabatmaz, D. M.; Greer, A.; Hersh, W. 
H.;Greer, E. M.; Murelli, R. P. J. Org. Chem. 2019, 84, 14670–14678.	
 
S4-	Williams, Y. D.; Meck, C.; Mohd, N.; Murelli, R. P. J. Org. Chem. 2013, 78, 11707-11713. 
S5- Gangjee, A.; Namjoshi, O. A.; Keller, S. N.; Smith, C. D. Bioorg. Med. Chem. 2011, 19, 
4355–4365.  
S6-Banwell, M. G.; Cameron, J. M.; Collis, M. P.; Crisp, G. T.; Gable, R. W.; Hamel, E.; 
Lambert, J. N.; Mackay, M. F.; Reum, M. E.; Scoble, J. A. Aust. J. Chem. 1991, 44, 705-728.  
S7-Wang, X.; Fu, J.-min; Snieckus, V. Helv. Chim. Acta 2012, 95, 2680–2694.  
 
 
 
 
 
 
 
	
